THERMO FISHER SCIENTIFIC INC. (Form: 10-Q, Received: 08/02/2019 11:54:49)

false--12-31Q2201900000977451170000001130000000.170.340.190.3811120000000012000000004315665614333582040.01450.00750.013750.01400.0150.01950.02150.028750.02950.020.030.0320.03650.03150.0330.0360.0410.04150.0450.0470.050.0530.062027-03-162024-09-122028-09-122026-01-232020-12-012029-07-242022-07-212037-07-242026-09-192025-04-152023-04-152027-08-152025-12-152023-01-152022-02-152021-08-152047-08-152024-02-012021-03-012020-05-012021-01-152044-02-012020-03-012019-07-242020-08-07P10YP8YP12YP8Y6MP5YP12YP7YP20YP10YP10YP7YP10YP10YP10YP7YP10YP30YP10YP10YP10YP10YP30YP10YP2YP2Y0.017640.0251500.034420us-gaap:OtherLiabilitiesCurrentus-gaap:OtherLiabilitiesNoncurrentus-gaap:OtherAssetsNoncurrent94000000470000003000000015000000100000020000001000000200000020000001000000400000040000002000000300000010000002000000100100500005000000us-gaap:OtherAssetsCurrentus-gaap:OtherAssetsNoncurrent2944488232882460 0000097745 2019-01-01 2019-06-29 0000097745 2019-06-29 0000097745 us-gaap:CommonStockMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes1.40Due2026Member 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotesFloatingRateDue2020Member 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes2.15Due2022Member 2019-01-01 2019-06-29 0000097745 tmo:A1.45SeniorNotesDue2027Member 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes1.50due2020Member 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes1.375Due2028Member 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes2.875Due2037Member 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes1.95Due2029Member 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes200Due2025Member 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes0.75Due2024Member 2019-01-01 2019-06-29 0000097745 2018-12-31 0000097745 us-gaap:ProductMember 2019-01-01 2019-06-29 0000097745 2019-03-31 2019-06-29 0000097745 2018-01-01 2018-06-30 0000097745 us-gaap:ServiceMember 2018-01-01 2018-06-30 0000097745 2018-04-01 2018-06-30 0000097745 us-gaap:ServiceMember 2019-01-01 2019-06-29 0000097745 us-gaap:ProductMember 2018-04-01 2018-06-30 0000097745 us-gaap:ServiceMember 2019-03-31 2019-06-29 0000097745 us-gaap:ServiceMember 2018-04-01 2018-06-30 0000097745 us-gaap:ProductMember 2019-03-31 2019-06-29 0000097745 us-gaap:ProductMember 2018-01-01 2018-06-30 0000097745 2017-12-31 0000097745 2018-06-30 0000097745 us-gaap:TreasuryStockMember 2019-03-30 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-29 0000097745 us-gaap:TreasuryStockMember 2018-03-31 0000097745 2019-03-30 0000097745 us-gaap:RetainedEarningsMember 2019-03-30 0000097745 us-gaap:TreasuryStockMember 2019-01-01 2019-06-29 0000097745 us-gaap:CommonStockMember 2018-03-31 0000097745 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0000097745 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000097745 us-gaap:CommonStockMember 2019-01-01 2019-06-29 0000097745 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0000097745 us-gaap:TreasuryStockMember 2018-06-30 0000097745 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-29 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000097745 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000097745 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000097745 us-gaap:CommonStockMember 2018-12-31 0000097745 us-gaap:TreasuryStockMember 2019-06-29 0000097745 us-gaap:RetainedEarningsMember 2017-12-31 0000097745 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-29 0000097745 2018-03-31 0000097745 us-gaap:CommonStockMember 2019-06-29 0000097745 us-gaap:CommonStockMember 2018-06-30 0000097745 us-gaap:TreasuryStockMember 2018-01-01 2018-06-30 0000097745 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000097745 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000097745 us-gaap:TreasuryStockMember 2019-03-31 2019-06-29 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-29 0000097745 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0000097745 us-gaap:CommonStockMember 2019-03-31 2019-06-29 0000097745 us-gaap:CommonStockMember 2017-12-31 0000097745 us-gaap:TreasuryStockMember 2017-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000097745 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0000097745 us-gaap:RetainedEarningsMember 2019-03-31 2019-06-29 0000097745 us-gaap:AdditionalPaidInCapitalMember 2019-06-29 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000097745 us-gaap:TreasuryStockMember 2018-12-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000097745 us-gaap:RetainedEarningsMember 2018-03-31 0000097745 us-gaap:CommonStockMember 2019-03-30 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 2019-06-29 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-30 0000097745 us-gaap:RetainedEarningsMember 2019-06-29 0000097745 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 2019-06-29 0000097745 us-gaap:RetainedEarningsMember 2018-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000097745 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000097745 us-gaap:AdditionalPaidInCapitalMember 2019-03-30 0000097745 us-gaap:RetainedEarningsMember 2018-06-30 0000097745 2019-01-01 0000097745 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000097745 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember tmo:AnatomicalPathologybusinessMember 2018-12-31 0000097745 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember tmo:AnatomicalPathologybusinessMember 2019-01-01 2019-06-29 0000097745 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-06-29 0000097745 tmo:BrammerBioMember 2019-04-30 2019-04-30 0000097745 tmo:BrammerBioMember 2019-04-30 0000097745 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember tmo:AnatomicalPathologybusinessMember 2019-06-28 0000097745 tmo:BrammerBioMember 2018-01-01 2018-12-31 0000097745 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember tmo:AnatomicalPathologybusinessMember 2019-06-28 2019-06-28 0000097745 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-06-29 0000097745 tmo:TradenamesAndOtherMember 2019-01-01 2019-06-29 0000097745 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2019-01-01 2019-06-29 0000097745 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember tmo:AnatomicalPathologybusinessMember 2018-01-01 2018-12-31 0000097745 tmo:BrammerBioMember tmo:TradenamesAndOtherMember 2019-04-30 0000097745 tmo:BrammerBioMember us-gaap:DevelopedTechnologyRightsMember 2019-04-30 0000097745 tmo:BrammerBioMember us-gaap:CustomerRelationshipsMember 2019-04-30 0000097745 2019-03-31 2019-06-29 0000097745 tmo:ConsumablesMember 2019-03-31 2019-06-29 0000097745 tmo:InstrumentsMember 2019-03-31 2019-06-29 0000097745 tmo:InstrumentsMember 2019-01-01 2019-06-29 0000097745 tmo:InstrumentsMember 2018-01-01 2018-06-30 0000097745 tmo:ConsumablesMember 2018-01-01 2018-06-30 0000097745 tmo:InstrumentsMember 2018-04-01 2018-06-30 0000097745 tmo:ConsumablesMember 2019-01-01 2019-06-29 0000097745 tmo:ConsumablesMember 2018-04-01 2018-06-30 0000097745 srt:NorthAmericaMember 2018-01-01 2018-06-30 0000097745 srt:AsiaPacificMember 2018-04-01 2018-06-30 0000097745 tmo:OtherRegionsMember 2018-04-01 2018-06-30 0000097745 tmo:OtherRegionsMember 2019-01-01 2019-06-29 0000097745 srt:AsiaPacificMember 2019-03-31 2019-06-29 0000097745 srt:NorthAmericaMember 2018-04-01 2018-06-30 0000097745 srt:EuropeMember 2019-03-31 2019-06-29 0000097745 srt:NorthAmericaMember 2019-03-31 2019-06-29 0000097745 srt:EuropeMember 2018-04-01 2018-06-30 0000097745 srt:AsiaPacificMember 2018-01-01 2018-06-30 0000097745 tmo:OtherRegionsMember 2018-01-01 2018-06-30 0000097745 tmo:OtherRegionsMember 2019-03-31 2019-06-29 0000097745 srt:AsiaPacificMember 2019-01-01 2019-06-29 0000097745 srt:EuropeMember 2018-01-01 2018-06-30 0000097745 srt:NorthAmericaMember 2019-01-01 2019-06-29 0000097745 srt:EuropeMember 2019-01-01 2019-06-29 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2019-01-01 2019-06-29 0000097745 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-06-29 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2018-04-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember 2018-01-01 2018-06-30 0000097745 us-gaap:IntersegmentEliminationMember 2019-03-31 2019-06-29 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2018-01-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember 2018-04-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2018-01-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2018-01-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2019-03-31 2019-06-29 0000097745 us-gaap:MaterialReconcilingItemsMember 2019-03-31 2019-06-29 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2019-01-01 2019-06-29 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2019-03-31 2019-06-29 0000097745 us-gaap:IntersegmentEliminationMember 2018-04-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2018-04-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember tmo:SpecialtyDiagnosticsMember 2018-04-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2019-01-01 2019-06-29 0000097745 us-gaap:OperatingSegmentsMember tmo:AnalyticalInstrumentsMember 2019-03-31 2019-06-29 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2018-04-01 2018-06-30 0000097745 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-06-29 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2019-03-31 2019-06-29 0000097745 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember tmo:LifeSciencesSolutionsMember 2019-01-01 2019-06-29 0000097745 us-gaap:MaterialReconcilingItemsMember 2018-04-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember tmo:LaboratoryProductsandServicesMember 2018-01-01 2018-06-30 0000097745 us-gaap:IntersegmentEliminationMember 2018-01-01 2018-06-30 0000097745 us-gaap:OperatingSegmentsMember 2019-01-01 2019-06-29 0000097745 us-gaap:OperatingSegmentsMember 2019-03-31 2019-06-29 0000097745 country:US 2018-04-01 2018-06-30 0000097745 country:US 2018-01-01 2018-06-30 0000097745 country:CN 2018-04-01 2018-06-30 0000097745 country:CN 2018-01-01 2018-06-30 0000097745 country:US 2019-01-01 2019-06-29 0000097745 country:CN 2019-03-31 2019-06-29 0000097745 tmo:AllOtherCountriesMember 2018-04-01 2018-06-30 0000097745 tmo:AllOtherCountriesMember 2019-03-31 2019-06-29 0000097745 tmo:AllOtherCountriesMember 2018-01-01 2018-06-30 0000097745 tmo:AllOtherCountriesMember 2019-01-01 2019-06-29 0000097745 country:US 2019-03-31 2019-06-29 0000097745 country:CN 2019-01-01 2019-06-29 0000097745 us-gaap:InlandRevenueSingaporeIRASMember 2018-01-01 2018-06-30 0000097745 2019-01-01 2019-03-30 0000097745 us-gaap:InlandRevenueSingaporeIRASMember 2019-01-01 2019-06-29 0000097745 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-29 0000097745 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000097745 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000097745 us-gaap:EmployeeStockOptionMember 2019-03-31 2019-06-29 0000097745 tmo:SeniorNotes450Due2021Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes3.00Due2023Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes360Due2021Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes1.40Due2026Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotesFloatingRateDue2020Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes500Due2021Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:A1.45SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes4.10Due2047Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes415Due2024Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotesFloatingRateDue2019Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes3.65Due2025Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 us-gaap:CommercialPaperMember 2019-06-29 0000097745 tmo:SeniorNotes200Due2025Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes2.95Due2026Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes330Due2022Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes415Due2024Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes360Due2021Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 us-gaap:CommercialPaperMember 2018-12-31 0000097745 tmo:SeniorNotes1.375Due2028Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes0.75Due2024Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes1.50due2020Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes530Due2044Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotesFloatingRateDue2019Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes2.15Due2022Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes2.875Due2037Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes2.95Due2026Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes1.95Due2029Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes450Due2021Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes330Due2022Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes3.65Due2025Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes500Due2021Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes4.10Due2047Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:OtherDebtMember 2018-12-31 0000097745 tmo:SeniorNotes3.00Due2023Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes1.50due2020Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes3.20Due2027Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes470Due2020Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes600Due2020Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:A1.45SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes2.15Due2022Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes315Due2023Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotesFloatingRateDue2020Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes0.75Due2024Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes450Due2021Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes315Due2023Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes1.40Due2026Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes200Due2025Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes3.00Due2023Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes3.20Due2027Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes600Due2020Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:OtherDebtMember 2019-06-29 0000097745 tmo:SeniorNotes360Due2021Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes530Due2044Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes1.375Due2028Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes2.875Due2037Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:SeniorNotes470Due2020Member us-gaap:SeniorNotesMember 2018-12-31 0000097745 tmo:SeniorNotes1.95Due2029Member us-gaap:SeniorNotesMember 2019-06-29 0000097745 tmo:U.S.CommercialPaperProgramMember us-gaap:CommercialPaperMember 2019-01-01 2019-06-29 0000097745 us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 us-gaap:CrossCurrencyInterestRateContractMember 2019-06-29 0000097745 us-gaap:InterestRateSwapMember 2019-06-29 0000097745 us-gaap:RevolvingCreditFacilityMember 2019-06-29 0000097745 us-gaap:CommercialPaperMember 2019-01-01 2019-06-29 0000097745 us-gaap:RevolvingCreditFacilityMember 2019-01-01 2019-06-29 0000097745 tmo:EuroCommercialPaperProgramMember us-gaap:CommercialPaperMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes3.00Due2023Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes450Due2021Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes3.20Due2027Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes3.65Due2025Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes500Due2021Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes2.15Due2022Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes530Due2044Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes0.75Due2024Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes600Due2020Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes330Due2022Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes2.875Due2037Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes1.375Due2028Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes315Due2023Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes4.10Due2047Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes360Due2021Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes1.40Due2026Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes470Due2020Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes200Due2025Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotesFloatingRateDue2019Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes2.95Due2026Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes1.50due2020Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes1.95Due2029Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotesFloatingRateDue2020Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:A1.45SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 tmo:SeniorNotes415Due2024Member us-gaap:SeniorNotesMember 2019-01-01 2019-06-29 0000097745 srt:MinimumMember 2019-01-01 2019-06-29 0000097745 srt:MaximumMember 2019-06-29 0000097745 us-gaap:GuaranteeTypeOtherMember 2019-06-29 0000097745 srt:MaximumMember 2019-01-01 2019-06-29 0000097745 srt:MinimumMember 2019-06-29 0000097745 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-29 0000097745 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000097745 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-29 0000097745 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-06-29 0000097745 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-06-29 0000097745 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-06-29 0000097745 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000097745 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-06-29 0000097745 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000097745 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000097745 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000097745 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-06-29 0000097745 us-gaap:FairValueMeasurementsRecurringMember 2019-06-29 0000097745 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000097745 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-29 0000097745 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000097745 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-29 0000097745 us-gaap:OtherNoncurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000097745 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-06-29 0000097745 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-29 0000097745 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-29 0000097745 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-29 0000097745 tmo:ContingentConsiderationMember 2018-04-01 2018-06-30 0000097745 tmo:ContingentConsiderationMember 2019-03-30 0000097745 tmo:ContingentConsiderationMember 2018-01-01 2018-06-30 0000097745 tmo:ContingentConsiderationMember 2019-01-01 2019-06-29 0000097745 tmo:ContingentConsiderationMember 2018-12-31 0000097745 tmo:ContingentConsiderationMember 2018-06-30 0000097745 tmo:ContingentConsiderationMember 2019-06-29 0000097745 tmo:ContingentConsiderationMember 2018-03-31 0000097745 tmo:ContingentConsiderationMember 2019-03-31 2019-06-29 0000097745 tmo:ContingentConsiderationMember 2017-12-31 0000097745 us-gaap:InterestRateSwapMember 2018-12-31 0000097745 us-gaap:ForeignExchangeContractMember 2018-12-31 0000097745 us-gaap:CrossCurrencyInterestRateContractMember 2018-12-31 0000097745 us-gaap:ForeignExchangeContractMember 2019-06-29 0000097745 us-gaap:SeniorNotesMember 2019-06-29 0000097745 us-gaap:SeniorNotesMember 2018-12-31 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2019-03-31 2019-06-29 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2019-03-31 2019-06-29 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2018-01-01 2018-06-30 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherExpenseMember 2018-04-01 2018-06-30 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2019-01-01 2019-06-29 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2019-01-01 2019-06-29 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherExpenseMember 2018-01-01 2018-06-30 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2018-01-01 2018-06-30 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2019-01-01 2019-06-29 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherExpenseMember 2019-01-01 2019-06-29 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-31 2019-06-29 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2018-01-01 2018-06-30 0000097745 tmo:ForeigncurrencydenominateddebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-04-01 2018-06-30 0000097745 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2018-04-01 2018-06-30 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-04-01 2018-06-30 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2019-01-01 2019-06-29 0000097745 tmo:ForeigncurrencydenominateddebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-03-31 2019-06-29 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-06-30 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2019-03-31 2019-06-29 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2018-04-01 2018-06-30 0000097745 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherExpenseMember 2019-03-31 2019-06-29 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2019-03-31 2019-06-29 0000097745 tmo:ForeigncurrencydenominateddebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-06-29 0000097745 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-06-29 0000097745 tmo:ForeigncurrencydenominateddebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-06-30 0000097745 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherExpenseMember 2018-04-01 2018-06-30 0000097745 tmo:LongtermObligationsMember 2018-12-31 0000097745 tmo:LongtermObligationsMember 2019-06-29 0000097745 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000097745 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000097745 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000097745 tmo:LifeSciencesSolutionsMember 2019-01-01 2019-06-29 0000097745 tmo:SpecialtyDiagnosticsMember 2019-01-01 2019-06-29 0000097745 tmo:AnalyticalInstrumentsMember 2019-01-01 2019-06-29 0000097745 us-gaap:CorporateMember 2019-01-01 2019-06-29 0000097745 tmo:LaboratoryProductsandServicesMember 2019-01-01 2019-06-29 0000097745 us-gaap:FacilityClosingMember 2019-01-01 2019-06-29 0000097745 us-gaap:OtherRestructuringMember 2019-01-01 2019-06-29 0000097745 us-gaap:FacilityClosingMember 2018-12-31 0000097745 us-gaap:EmployeeSeveranceMember 2018-12-31 0000097745 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-06-29 0000097745 us-gaap:OtherRestructuringMember 2018-12-31 0000097745 us-gaap:EmployeeSeveranceMember 2019-06-29 0000097745 us-gaap:OtherRestructuringMember 2019-06-29 0000097745 us-gaap:FacilityClosingMember 2019-06-29 0000097745 tmo:ChargesForCashCompensationContractuallyDueToEmployeesOfAcquiredBusinessMember 2019-01-01 2019-06-29 0000097745 us-gaap:ScenarioForecastMember 2019-08-02 0000097745 tmo:LaboratoryProductsandServicesMember 2019-03-31 2019-06-29 0000097745 tmo:AnalyticalInstrumentsMember 2019-03-31 2019-06-29 0000097745 tmo:SpecialtyDiagnosticsMember 2019-03-31 2019-06-29 0000097745 tmo:LifeSciencesSolutionsMember 2019-03-31 2019-06-29 0000097745 us-gaap:CorporateMember 2019-03-31 2019-06-29 xbrli:shares xbrli:pure iso4217:USD xbrli:shares iso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarter Ended June 29, 2019 or

☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number 1-8002

THERMO FISHER SCIENTIFIC INC.

(Exact name of Registrant as specified in its charter)



Delaware	04-2209186
(State of incorporation)	(I.R.S. Employer Identification No.)

168 Third Avenue

Waltham, Massachusetts 02451

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $1.00 par value	TMO	New York Stock Exchange
Floating Rate Notes due 2020	TMO /20A	New York Stock Exchange
1.500% Notes due 2020	TMO 20A	New York Stock Exchange
2.150% Notes due 2022	TMO 22A	New York Stock Exchange
0.750% Notes due 2024	TMO 24A	New York Stock Exchange
2.000% Notes due 2025	TMO 25	New York Stock Exchange
1.400% Notes due 2026	TMO 26A	New York Stock Exchange
1.450% Notes due 2027	TMO 27	New York Stock Exchange
1.375% Notes due 2028	TMO 28	New York Stock Exchange
1.950% Notes due 2029	TMO 29	New York Stock Exchange
2.875% Notes due 2037	TMO 37	New York Stock Exchange

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months. Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐

Smaller reporting company ☐ Emerging growth company ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 29, 2019, the Registrant had 400,475,744 shares of Common Stock outstanding.

THERMO FISHER SCIENTIFIC INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED JUNE 29, 2019



	TABLE OF CONTENTS
		Page
	PART I

Item 1.	Financial Statements (Unaudited)	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	39

Item 4.	Controls and Procedures	40

	PART II

Item 1.	Legal Proceedings	40

Item 1A.	Risk Factors	40

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	46

Item 6.	Exhibits	46

THERMO FISHER SCIENTIFIC INC.


PART I	FINANCIAL INFORMATION


Item 1.	Financial Statements

CONSOLIDATED BALANCE SHEET

(Unaudited)



	June 29,			December 31,
(In millions except share and per share amounts)	2019			2018

Assets
Current Assets:
Cash and cash equivalents	$	2,288		$	2,103
Accounts receivable, less allowances of $113 and $117	4,129			4,136
Inventories	3,209			3,005
Other current assets	1,597			1,381

Total current assets	11,223			10,625

Property, Plant and Equipment, Net	4,394			4,165
Acquisition-related Intangible Assets, Net	14,863			14,978
Other Assets	1,733			1,117
Goodwill	25,757			25,347

Total Assets	$	57,970		$	56,232

Liabilities and Shareholders' Equity
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	$	2,377		$	1,271
Accounts payable	1,391			1,615
Accrued payroll and employee benefits	809			982
Contract liabilities	1,062			809
Other accrued expenses	1,870			1,470

Total current liabilities	7,509			6,147

Deferred Income Taxes	1,936			2,265
Other Long-term Liabilities	3,133			2,515
Long-term Obligations	16,663			17,719

Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 433,358,204 and 431,566,561 shares issued	433			432
Capital in excess of par value	14,887			14,621
Retained earnings	20,482			18,696
Treasury stock at cost, 32,882,460 and 29,444,882 shares	(4,443		)	(3,665		)
Accumulated other comprehensive items	(2,630		)	(2,498		)

Total shareholders' equity	28,729			27,586

Total Liabilities and Shareholders' Equity	$	57,970		$	56,232

The accompanying notes are an integral part of these consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

CONSOLIDATED STATEMENT OF INCOME

(Unaudited)



	Three Months Ended						Six Months Ended
	June 29,			June 30,			June 29,			June 30,
(In millions except per share amounts)	2019			2018			2019			2018

Revenues
Product revenues	$	4,827		$	4,708		$	9,547		$	9,236
Service revenues	1,489			1,370			2,894			2,695

Total revenues	6,316			6,078			12,441			11,931

Costs and Operating Expenses:
Cost of product revenues	2,478			2,390			4,892			4,715
Cost of service revenues	1,015			950			2,019			1,898
Selling, general and administrative expenses	1,565			1,542			3,093			3,057
Research and development expenses	246			242			494			476
Restructuring and other (income) costs, net	(484		)	17			(473		)	62

Total costs and operating expenses	4,820			5,141			10,025			10,208

Operating Income	1,496			937			2,416			1,723
Other Expense, Net	(103		)	(131		)	(206		)	(283		)

Income Before Income Taxes	1,393			806			2,210			1,440
Provision for Income Taxes	(274		)	(54		)	(276		)	(109		)

Net Income	$	1,119		$	752		$	1,934		$	1,331

Earnings per Share
Basic	$	2.80		$	1.87		$	4.84		$	3.31
Diluted	$	2.77		$	1.85		$	4.80		$	3.28

Weighted Average Shares
Basic	400			403			400			402
Diluted	403			406			403			406

The accompanying notes are an integral part of these consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(Unaudited)



	Three Months Ended						Six Months Ended
	June 29,			June 30,			June 29,			June 30,
(In millions)	2019			2018			2019			2018

Comprehensive Income
Net Income	$	1,119		$	752		$	1,934		$	1,331

Other Comprehensive Items:
Currency translation adjustment (net of tax provision (benefit) of ($30), $94, $15 and $47)	(116		)	(462		)	(131		)	(415		)
Unrealized gains and losses on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax benefit of $1, $1, $2 and $2)	3			2			5			4
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of ($4), $2, ($4) and $1)	(12		)	5			(11		)	3
Amortization of net loss included in net periodic pension cost (net of tax benefit of $1, $2, $2 and $3)	4			6			5			8

Total other comprehensive items	(121		)	(449		)	(132		)	(400		)

Comprehensive Income	$	998		$	303		$	1,802		$	931

The accompanying notes are an integral part of these consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited)



	Six Months Ended
	June 29,			June 30,
(In millions)	2019			2018

Operating Activities
Net income	$	1,934		$	1,331

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	275			261
Amortization of acquisition-related intangible assets	851			885
Change in deferred income taxes	(392		)	(99		)
Gain on sale of business	(505		)	—
Non-cash stock-based compensation	96			91
Other non-cash expenses, net	48			63
Changes in assets and liabilities, excluding the effects of acquisitions and disposition:
Accounts receivable	5			(97		)
Inventories	(273		)	(195		)
Other assets	(179		)	(296		)
Accounts payable	(202		)	(20		)
Other liabilities	319			(359		)
Contributions to retirement plans	(34		)	(43		)

Net cash provided by operating activities	1,943			1,522

Investing Activities
Acquisitions, net of cash acquired	(1,686		)	(59		)
Proceeds from sale of business, net of cash divested	1,126			—
Purchase of property, plant and equipment	(421		)	(301		)
Proceeds from sale of property, plant and equipment	12			3
Other investing activities, net	19			(7		)

Net cash used in investing activities	(950		)	(364		)

Financing Activities
Repayment of debt	(3		)	(1,353		)
Proceeds from issuance of commercial paper	1,895			2,761
Repayments of commercial paper	(1,855		)	(2,655		)
Purchases of company common stock	(750		)	—
Dividends paid	(144		)	(129		)
Net proceeds from issuance of company common stock under employee stock plans	122			78
Other financing activities	—			(50		)

Net cash used in financing activities	(735		)	(1,348		)

Exchange Rate Effect on Cash	(61		)	(215		)

Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash	197			(405		)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	2,117			1,361

Cash, Cash Equivalents and Restricted Cash at End of Period	$	2,314		$	956

The accompanying notes are an integral part of these consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY

(Unaudited)



	Common Stock			Capital in Excess of Par Value		Retained Earnings			Treasury Stock				Accumulated Other Comprehensive Items			Total Shareholders' Equity
(In millions)	Shares	Amount		Capital in Excess of Par Value		Retained Earnings			Shares	Amount			Accumulated Other Comprehensive Items			Total Shareholders' Equity

	Three Months Ended June 29, 2019
Balance at March 30, 2019	433	$	433	$	14,771	$	19,439		33	$	(4,441	)	$	(2,509	)	$	27,693
Issuance of shares under employees' and directors' stock plans	—	—		64		—			—	(2		)	—			62
Stock-based compensation	—	—		52		—			—	—			—			52
Dividends declared ($0.19 per share)	—	—		—		(76		)	—	—			—			(76		)
Net income	—	—		—		1,119			—	—			—			1,119
Other comprehensive items	—	—		—		—			—	—			(121		)	(121		)
Balance at June 29, 2019	433	$	433	$	14,887	$	20,482		33	$	(4,443	)	$	(2,630	)	$	28,729

	Three Months Ended June 30, 2018
Balance at March 31, 2018	429	$	429	$	14,319	$	16,542		27	$	(3,125	)	$	(2,042	)	$	26,123
Issuance of shares under employees' and directors' stock plans	1	1		41		—			—	(3		)	—			39
Stock-based compensation	—	—		48		—			—	—			—			48
Dividends declared ($0.17 per share)	—	—		—		(68		)	—	—			—			(68		)
Net income	—	—		—		752			—	—			—			752
Other comprehensive items	—	—		—		—			—	—			(449		)	(449		)
Balance at June 30, 2018	430	$	430	$	14,408	$	17,226		27	$	(3,128	)	$	(2,491	)	$	26,445

	Six Months Ended June 29, 2019
Balance at December 31, 2018	432	$	432	$	14,621	$	18,696		29	$	(3,665	)	$	(2,498	)	$	27,586
Cumulative effect of accounting change	—	—		—		4			—	—			—			4
Issuance of shares under employees' and directors' stock plans	1	1		170		—			1	(28		)	—			143
Stock-based compensation	—	—		96		—			—	—			—			96
Purchases of company common stock	—	—		—		—			3	(750		)	—			(750		)
Dividends declared ($0.38 per share)	—	—		—		(152		)	—	—			—			(152		)
Net income	—	—		—		1,934			—	—			—			1,934
Other comprehensive items	—	—		—		—			—	—			(132		)	(132		)
Balance at June 29, 2019	433	$	433	$	14,887	$	20,482		33	$	(4,443	)	$	(2,630	)	$	28,729

	Six Months Ended June 30, 2018
Balance at December 31, 2017	428	$	428	$	14,177	$	15,914		27	$	(3,103	)	$	(2,003	)	$	25,413
Cumulative effect of accounting changes	—	—		—		118			—	—			(88		)	30
Issuance of shares under employees' and directors' stock plans	2	2		113		—			—	(25		)	—			90
Stock-based compensation	—	—		91		—			—	—			—			91
Dividends declared ($0.34 per share)	—	—		—		(137		)	—	—			—			(137		)
Net income	—	—		—		1,331			—	—			—			1,331
Other comprehensive items	—	—		—		—			—	—			(400		)	(400		)
Other	—	—		27		—			—	—			—			27
Balance at June 30, 2018	430	$	430	$	14,408	$	17,226		27	$	(3,128	)	$	(2,491	)	$	26,445

The accompanying notes are an integral part of these consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


Note 1.	Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.

Interim Financial Statements

The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at June 29, 2019, the results of operations for the three- and six-month periods ended June 29, 2019 and June 30, 2018, and the cash flows for the six-month periods ended June 29, 2019 and June 30, 2018. Interim results are not necessarily indicative of results for a full year.

The consolidated balance sheet presented as of December 31, 2018, has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2018 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC).

Note 1 to the consolidated financial statements for 2018 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. Except for the accounting for leases, as noted below, there have been no material changes in the company’s significant accounting policies during the six months ended June 29, 2019.

Leases

The company determines whether an arrangement is, or contains, a lease at inception. Prior to 2019, the company generally accounted for operating lease payments by charging them to expense as incurred. Beginning in 2019, operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet. Classification of operating lease liabilities as either current or noncurrent is based on the expected timing of payments due under the company’s obligations.

Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company recognizes lease expense for these leases on a straight-line basis over the lease term.

Because most of the company’s leases do not provide an implicit rate, the company estimates incremental borrowing rates based on the information available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease terms may include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

As a lessee, the company accounts for the lease and non-lease components as a single lease component.

See Note 9 additional information about the company's leases.

Contract-related Balances

Current contract assets and noncurrent contract assets are included within other current assets and other assets, respectively, in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows:

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)



	June 29,		December 31,
(In millions)	2019		2018

Current Contract Assets, Net	$	646	$	459
Noncurrent Contract Assets, Net	13		15
Current Contract Liabilities	1,062		809
Noncurrent Contract Liabilities	532		355

In the first six months of 2019, the company recognized revenue of $532 million that was included in the contract liabilities balance at December 31, 2018. Contract assets increased in the first six months of 2019 due to the timing of billing. Contract liabilities increased during the first six months of 2019 primarily due to an advance payment from a customer and an acquisition.

Warranty Obligations

The liability for warranties is included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows:



	Six Months Ended
	June 29,			June 30,
(In millions)	2019			2018

Beginning Balance	$	92		$	87
Provision charged to income	53			58
Usage	(55		)	(53		)
Adjustments to previously provided warranties, net	(1		)	(2		)
Currency translation	—			(2		)

Ending Balance	$	89		$	88

Inventories

The components of inventories are as follows:



	June 29,		December 31,
(In millions)	2019		2018

Raw Materials	$	923	$	812
Work in Process	495		430
Finished Goods	1,791		1,763

Inventories	$	3,209	$	3,005

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In August 2018, the FASB issued new guidance to modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The company expects to adopt the guidance when it is effective in 2020 using a retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures.

In August 2018, the FASB issued new guidance to modify the disclosure requirements on fair value measurements. The company expects to adopt the guidance when it is effective in 2020 with some items requiring a prospective method and others

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

requiring a retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s disclosures.

In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. The company expects to adopt the guidance when it is effective in 2020 using a modified retrospective method. The adoption of this guidance is not expected to have a material impact on the company’s consolidated financial statements.

In February 2016, the FASB issued new guidance which requires lessees to record most leases on their balance sheets as lease liabilities, initially measured at the present value of the future lease payments, with corresponding right-of-use assets. The new guidance also sets forth new disclosure requirements related to leases. During 2017 - 2019, the FASB issued additional guidance and clarification. The guidance became effective for the company in 2019. The company has elected to adopt the guidance using a modified retrospective method, by applying the transition approach as of the beginning of the period of adoption. Comparative periods have not been restated. As permitted upon transition, the company did not reassess whether any expired or existing contracts were or contained embedded leases, the lease classification for any expired or existing leases, initial direct costs for any leases, or whether land easements met the definition of a lease if they were not accounted for as leases under the prior guidance. Adoption of the new guidance impacted the company’s Consolidated Balance Sheet as follows:



(In millions)	December 31, 2018 as Reported		Impact of Adopting New Lease Guidance		January 1, 2019 As Adopted

Other Assets	$	1,117	$	641	$	1,758
Other Accrued Expenses	1,470		132		1,602
Other Long-term Liabilities	2,515		505		3,020
Retained Earnings	18,696		4		18,700


Note 2.	Acquisitions and Dispositions

The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.

Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

On April 30, 2019, the company acquired, within the Laboratory Products and Services segment, Brammer Bio for approximately $1.67 billion in cash. Brammer Bio is a leading viral vector contract development and manufacturing organization for gene and cell therapies. The acquisition expands the segment's contract manufacturing capabilities. Revenues of Brammer Bio were approximately $140 million in 2018. The purchase price exceeded the fair value of the identifiable net assets and, accordingly, $952 million was allocated to goodwill, $411 million of which is tax deductible.

In addition, in 2019 the company acquired, within the Analytical Instruments segment, a Slovakia-based provider of mass spectrometry software used for identification of compounds, for an aggregate purchase price of $14 million.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

The components of the purchase price and net assets acquired for Brammer Bio are as follows:



(In millions)	Brammer Bio

Purchase Price
Cash paid	$	1,709
Cash acquired	(36		)

	$	1,673

Net Assets Acquired
Current assets	$	52
Property, plant and equipment	148
Definite-lived intangible assets:
Customer relationships	744
Product technology	44
Tradenames	7
Goodwill	952
Other assets	49
Contract liabilities	(110		)
Deferred tax liabilities	(105		)
Other liabilities assumed	(108		)

	$	1,673

The weighted-average amortization periods for definite-lived intangible assets acquired in 2019 are 14 years for customer relationships, 13 years for product technology and 2 years for tradenames. The weighted average amortization period for all definite-lived intangible assets acquired in 2019 is 14 years.

The preliminary allocation of the purchase price for Brammer Bio was based on estimates of the fair value of the net assets acquired and is subject to adjustment upon finalization of the valuation of the acquired intangible assets and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions. The company expects to complete the valuation in the third quarter of 2019.

In 2018, the company entered into an agreement to acquire Gatan, Inc., a wholly owned subsidiary of Roper Technologies, Inc. In June 2019, as publicly announced, Roper Technologies and the company agreed to withdraw from the proposed transaction.

Disposition

On June 28, 2019, the company sold its Anatomical Pathology business to PHC Holdings Corporation for $1.13 billion, net of cash divested. The business was part of the Specialty Diagnostics segment. The sale of this business resulted in a pre-tax gain of approximately $505 million, included in restructuring and other (income) costs, net. Revenues in 2019, through the date of sale, and the full year 2018 of the business sold were approximately $115 million and $238 million, respectively, net of retained sales through the company's healthcare market channel business. The assets and liabilities of the Anatomical Pathology business were as follows on December 31, 2018:



(In millions)	December 31, 2018

Current Assets	$	81
Long-term Assets	528
Current Liabilities	34
Long-term Liabilities	24

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)


Note 3.	Revenue

Disaggregated Revenue

Revenue by type is as follows:



	Three Months Ended				Six Months Ended
	June 29,		June 30,		June 29,		June 30,
(In millions)	2019		2018		2019		2018

Revenues
Consumables	3,268		3,178		$	6,498	6,289
Instruments	1,559		1,530		3,049		2,947
Services	1,489		1,370		2,894		2,695

Consolidated revenues	$	6,316	$	6,078	$	12,441	$	11,931

Revenue by geographic region is as follows:



	Three Months Ended				Six Months Ended
	June 29,		June 30,		June 29,		June 30,
(In millions)	2019		2018		2019		2018

Revenues (a)
North America	$	3,230	$	3,042	$	6,289	$	5,945
Europe	1,536		1,549		3,055		3,067
Asia-Pacific	1,368		1,294		2,731		2,558
Other regions	182		193		366		361

Consolidated revenues	$	6,316	$	6,078	$	12,441	$	11,931


(a)	Revenues are attributed to regions based on customer location.

Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenue by reportable segment and other geographic data.

Remaining Performance Obligations

The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of June 29, 2019 was $7.07 billion. The company will recognize revenue for these performance obligations as they are satisfied, approximately 70% of which is expected to occur within the next twelve months.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)


Note 4.	Business Segment and Geographical Information

The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.

Business Segment Information



	Three Months Ended						Six Months Ended
	June 29,			June 30,			June 29,			June 30,
(In millions)	2019			2018			2019			2018

Revenues
Life Sciences Solutions	$	1,710		$	1,569		$	3,317		$	3,068
Analytical Instruments	1,324			1,311			2,646			2,568
Specialty Diagnostics	943			932			1,900			1,879
Laboratory Products and Services	2,633			2,550			5,146			4,963
Eliminations	(294		)	(284		)	(568		)	(547		)

Consolidated revenues	6,316			6,078			12,441			11,931

Segment Income (a)
Life Sciences Solutions	609			522			1,170			1,039
Analytical Instruments	286			291			568			537
Specialty Diagnostics	242			253			484			496
Laboratory Products and Services	345			337			630			617

Subtotal reportable segments (a)	1,482			1,403			2,852			2,689

Cost of revenues charges, net	(5		)	(5		)	(11		)	(8		)
Selling, general and administrative charges, net	(36		)	(3		)	(47		)	(11		)
Restructuring and other income (costs), net	484			(17		)	473			(62		)
Amortization of acquisition-related intangible assets	(429		)	(441		)	(851		)	(885		)

Consolidated operating income	1,496			937			2,416			1,723
Other expense, net (b)	(103		)	(131		)	(206		)	(283		)

Income from continuing operations before income taxes	$	1,393		$	806		$	2,210		$	1,440


(a)	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs/income, net; and amortization of acquisition-related intangibles.


(b)	The company does not allocate other expense, net to its segments.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

Geographical Information



	Three Months Ended				Six Months Ended
	June 29,		June 30,		June 29,		June 30,
(In millions)	2019		2018		2019		2018

Revenues (c)
United States	$	3,103	$	2,914	$	6,021	$	5,670
China	724		648		1,378		1,189
Other	2,489		2,516		5,042		5,072

Consolidated revenues	$	6,316	$	6,078	$	12,441	$	11,931


(c)	Revenues are attributed to countries based on customer location.


Note 5.	Other Expense, Net

The components of other expense, net, in the accompanying statement of income are as follows:



	Three Months Ended						Six Months Ended
	June 29,			June 30,			June 29,			June 30,
(In millions)	2019			2018			2019			2018

Interest Income	$	60		$	31		$	127		$	51
Interest Expense	(181		)	(170		)	(370		)	(333		)
Other Items, Net	18			8			37			(1		)

Other Expense, Net	$	(103	)	$	(131	)	$	(206	)	$	(283	)

Other Items, Net

In all periods, other items, net includes currency transaction gains and losses on monetary assets and liabilities and net periodic pension benefit cost/income, excluding the service cost component which is included in operating expenses on the accompanying statement of income.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)


Note 6.	Income Taxes

The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following:



	Six Months Ended
	June 29,			June 30,
(In millions)	2019			2018

Statutory Federal Income Tax Rate	21		%	21		%

Provision for Income Taxes at Statutory Rate	$	464		$	302

Increases (Decreases) Resulting From:
Foreign rate differential	(184		)	(127		)
Foreign exchange loss on inter-company debt refinancing	(62		)	—
Income tax credits	(137		)	(119		)
Global intangible low-taxed income	134			81
Foreign-derived intangible income	(24		)	(22		)
Withholding taxes	31			11
Singapore tax holiday	(13		)	(19		)
Transition tax and other impacts of U.S. tax reform	(20		)	70
Provision for (reversal of) tax reserves, net	43			(49		)
Excess tax benefits from stock options and restricted stock units	(50		)	(36		)
Basis difference on disposal of business	64			—
Other, net	30			17

Provision for income taxes	$	276		$	109

In the first quarter of 2019, the company recorded a $62 million income tax benefit related to a foreign exchange loss for tax purposes on certain intercompany financing arrangements. In the second quarter of 2019, the company recorded a tax provision of $187 million related to the gain on sale of the Anatomical Pathology business. In addition, in the second quarter of 2019, the company implemented foreign tax credit planning in Sweden which resulted in $75 million of foreign tax credits, with no related incremental U.S. income tax expense.

During the first six months of 2019, the company recorded a net tax provision of $1 million to adjust the impacts of U.S. tax reform based on final regulations issued by the U.S. Treasury in January and June 2019. The income tax provision consists of an incremental benefit of $20 million and a $7 million reduction of related unrecognized tax benefits in the first quarter of 2019 and a $28 million charge to increase an unrecognized tax benefit in the second quarter of 2019.

The company has significant activities in Singapore and has received considerable tax incentives. The local taxing authority granted the company pioneer company status which provides an incentive encouraging companies to undertake activities that have the effect of promoting economic or technological development in Singapore. This incentive equates to a tax exemption on earnings associated with most of the company’s manufacturing activities in Singapore and continues through December 31, 2026. In 2019 and 2018, the impact of this tax holiday decreased the annual effective tax rates by 0.6 percentage points and 1.3 percentage points, respectively, and increased diluted earnings per share by approximately $0.03 and $0.05, respectively.

Unrecognized Tax Benefits

As of June 29, 2019, the company had $1.50 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:



(In millions)	2019

Balance at Beginning of Year	$	1,442
Additions for tax positions of current year	4
Additions for tax positions of prior years	62
Reductions for tax positions of prior years	(12		)

Balance at End of Period	$	1,496


Note 7.	Earnings per Share



	Three Months Ended				Six Months Ended
	June 29,		June 30,		June 29,		June 30,
(In millions except per share amounts)	2019		2018		2019		2018

Net Income	$	1,119	$	752	$	1,934	$	1,331

Basic Weighted Average Shares	400		403		400		402
Plus Effect of:
Stock options and restricted units	3		3		3		4

Diluted Weighted Average Shares	403		406		403		406

Basic Earnings per Share	$	2.80	$	1.87	$	4.84	$	3.31

Diluted Earnings per Share	$	2.77	$	1.85	$	4.80	$	3.28

Antidilutive Stock Options Excluded from Diluted Weighted Average Shares	1		2		1		2

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)


Note 8.	Debt and Other Financing Arrangements



	Effective Interest Rate at June 29,		June 29,			December 31,
(Dollars in millions)	2019		2019			2018

Commercial Paper	—	%	$	737		$	693
Floating Rate 2-Year Senior Notes, Due 7/24/2019 (euro-denominated)	0.10	%	569			574
6.00% 10-Year Senior Notes, Due 3/1/2020	2.97	%	750			750
4.70% 10-Year Senior Notes, Due 5/1/2020	4.23	%	300			300
Floating Rate 2-Year Senior Notes, Due 8/7/2020 (euro-denominated)	0.17	%	682			688
1.50% 5-Year Senior Notes, Due 12/1/2020 (euro-denominated)	1.62	%	483			487
5.00% 10-Year Senior Notes, Due 1/15/2021	3.25	%	400			400
4.50% 10-Year Senior Notes, Due 3/1/2021	6.14	%	1,000			1,000
3.60% 10-Year Senior Notes, Due 8/15/2021	5.71	%	1,100			1,100
3.30% 7-Year Senior Notes, Due 2/15/2022	3.42	%	800			800
2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated)	2.28	%	569			574
3.15% 10-Year Senior Notes, Due 1/15/2023	3.30	%	800			800
3.00% 7-Year Senior Notes, Due 4/15/2023	5.81	%	1,000			1,000
4.15% 10-Year Senior Notes, Due 2/1/2024	4.16	%	1,000			1,000
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)	0.94	%	1,137			1,147
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)	2.10	%	728			734
3.65% 10-Year Senior Notes, Due 12/15/2025	3.77	%	350			350
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)	1.53	%	796			802
2.95% 10-Year Senior Notes, Due 9/19/2026	3.19	%	1,200			1,200
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)	1.66	%	569			574
3.20% 10-Year Senior Notes, Due 8/15/2027	3.39	%	750			750
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)	1.46	%	682			688
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)	2.08	%	796			802
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)	2.94	%	796			802
5.30% 30-Year Senior Notes, Due 2/1/2044	5.37	%	400			400
4.10% 30-Year Senior Notes, Due 8/15/2047	4.23	%	750			750
Other			20			21

Total Borrowings at Par Value			19,164			19,186
Fair Value Hedge Accounting Adjustments			(19		)	(93		)
Unamortized Discount, Net			(31		)	(21		)
Unamortized Debt Issuance Costs			(74		)	(82		)

Total Borrowings at Carrying Value			19,040			18,990
Less: Short-term Obligations and Current Maturities			2,377			1,271

Long-term Obligations			$	16,663		$	17,719

The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium, the amortization of any debt issuance costs and, if applicable, adjustments related to hedging.

See Note 12 for fair value information pertaining to the company’s long-term obligations.

Credit Facilities

The company has a revolving credit facility with a bank group that provides for up to $2.50 billion of unsecured multi-currency revolving credit. The facility expires in July 2021. The agreement calls for interest at either a LIBOR-based rate, a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

this type. The covenants in our revolving credit facility (the Facility) include a Consolidated Leverage Ratio (total debt-to-Consolidated EBITDA) and a Consolidated Interest Coverage Ratio (Consolidated EBITDA to Consolidated Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a maximum Consolidated Leverage Ratio of 3.5:1.0. The company has also agreed that so long as any lender has any commitment under the Facility or any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.0:1.0 as of the last day of any fiscal quarter. As of June 29, 2019, no borrowings were outstanding under the Facility, although available capacity was reduced by approximately $86 million as a result of outstanding letters of credit.

Commercial Paper Programs

The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of June 29, 2019, outstanding borrowings under these programs were $737 million with a weighted average remaining period to maturity of 46 days and are classified as short-term obligations in the accompanying balance sheet.

Senior Notes

Interest on the floating rate senior notes is payable quarterly. Interest is payable annually on the other euro-denominated senior notes and semi-annually on all other senior notes. Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements.

In 2018, Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of the company, issued the Floating Rate Senior Notes due 2020 included in the table above. This subsidiary has no independent function other than financing activities. The Floating Rate Senior Notes due 2020 are fully and unconditionally guaranteed by the company and no other subsidiaries of the company have guaranteed the obligations.

Interest Rate Swap Arrangements and related Cross-currency Interest Rate Swap Arrangements

The company has entered into LIBOR-based interest rate swap arrangements with various banks on several of its outstanding senior notes. The aggregate amounts of the swaps are equal to the principal amounts of the notes and the payment dates of the swaps coincide with the interest payment dates of the notes. The swap contracts provide for the company to pay a variable interest rate and receive a fixed rate. The variable interest rates reset monthly. The swaps have been accounted for as fair value hedges of the notes. See Note 12 for additional information on the interest rate swap arrangements and related cross-currency interest rate swap arrangements. The following table summarizes the outstanding interest rate swap arrangements on the company's senior notes at June 29, 2019:



	Aggregate Notional Amount		Pay Rate as of
(Dollars in millions)	Aggregate Notional Amount	Pay Rate	June 29, 2019		Receive Rate

4.50% Senior Notes due 2021 (a)	1,000	1-month LIBOR + 3.4420%	5.8820	%	4.50	%
3.60% Senior Notes due 2021	1,100	1-month LIBOR + 2.5150%	4.9093	%	3.60	%
3.00% Senior Notes due 2023 (a)	1,000	1-month LIBOR + 1.7640%	4.1583	%	3.00	%


(a)	The payments on $1.8 billion notional value of these interest rate swaps are offset in part by cross-currency interest rate swaps which effectively reduced the pay rate as of June 29, 2019 from a weighted average of 4.86% to a weighted average of 1.86%.

The company has entered into $1.8 billion notional value of cross-currency interest rate swaps, which effectively convert a portion of the semi-annual payments related to the variable rate, U.S. dollar denominated, LIBOR-based interest rate swaps to payments on variable rate, euro denominated, EURIBOR-based cross-currency interest rate swaps.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)


Note 9.	Leases

As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to terminate the arrangement within 1 year. The company’s finance leases are not material.

The company has guaranteed the residual value of three leased operating facilities with initial lease terms ending in 2019, 2020 and 2023. The company has agreed with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 8). The aggregate maximum guarantee under these three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated balance sheet as of June 29, 2019, but exclude any amounts for residual value guarantees.

As a lessee, the consolidated statement of income includes pre-tax operating lease costs of $50 million and $98 million and pre-tax variable lease costs of $17 million and $26 million for the three and six months ended June 29, 2019, respectively. Lease costs arising from finance leases, short-term leases, and sublease income are not material.

Cash used in operating activities for payments of amounts included in the measurement of operating lease liabilities was $97 million in the six months ended June 29, 2019. Operating lease ROU assets of $36 million were obtained in exchange for new operating lease liabilities in the six months ended June 29, 2019.

The weighted-average remaining operating lease term was 6.2 years and the weighted average discount rate was 4.0% as of June 29, 2019.

ROU assets of $633 million as of June 29, 2019, are classified in other assets in the consolidated balance sheet. Operating lease liabilities of $157 million and $517 million as of June 29, 2019, are classified in other accrued expenses and other long-term liabilities, respectively, in the consolidated balance sheet.

As of June 29, 2019, future payments of operating lease liabilities are as follows:



(In millions)

Remainder of 2019	$	96
2020	171
2021	128
2022	96
2023	68
2024	49
2025 and Thereafter	159

Total Lease Payments	767
Less: Imputed Interest	93

Total Operating Lease Liability	$	674

As a lessor, operating leases, sales-type leases and direct financing leases are not material.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

As previously disclosed in the company's 2018 Annual Report on Form 10-K and under previous lease accounting guidance, the following is a summary of annual future minimum lease and rental commitments under noncancelable operating leases as of December 31, 2018:



(In millions)

2019	$	192
2020	158
2021	118
2022	86
2023	58
2024 and Thereafter	177

	$	789


Note 10.	Commitments and Contingencies

Environmental Matters

The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At June 29, 2019, the company’s total environmental liability was approximately $65 million. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows.

Litigation and Related Contingencies

There are various lawsuits and claims pending against the company including matters involving product liability, intellectual property, employment and commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below or in the company's 2018 financial statements and notes included in the company's Annual Report on Form 10-K filed with the SEC, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows.

Product Liability, Workers Compensation and Other Personal Injury Matters

For product liability, workers compensation and other personal injury matters, the company accrues the most likely amount or at least the minimum of the range of possible loss when a range of possible loss can be estimated. The company records estimated amounts due from insurers related to certain product liabilities as an asset. Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary materially. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.

Intellectual Property Matters

On June 3, 2013, Unisone Strategic IP filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging patent infringement by Life Technologies’ supply chain management system software, which operates with product "supply centers" installed at customer sites. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, and injunctive relief. On August 24, 2017, Unisone filed an appeal from a decision by the Patent Trial and Appeal Board (PTAB) that found the challenged patent claims invalid. The United States Court of Appeals for the Federal Circuit upheld the PTAB’s ruling finding the challenged claims in the Unisone patent invalid. Unisone had until March 11, 2019 to file an appeal with the United States Supreme Court. Unisone did not appeal that decision, and consequently the case before the United States District Court, which had been stayed pending the outcome of the PTAB decision, will resume with respect to similar Unisone patent claims that were not included in the PTAB proceeding.


Note 11.	Comprehensive Income

Comprehensive income combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as components of shareholders’ equity in the accompanying balance sheet.

Changes in each component of accumulated other comprehensive items, net of tax are as follows:



(In millions)	Currency Translation Adjustment			Unrealized Losses on Hedging Instruments			Pension and Other Postretirement Benefit Liability Adjustment			Total

Balance at December 31, 2018	$	(2,243	)	$	(52	)	$	(203	)	$	(2,498	)
Other comprehensive items before reclassifications	(131		)	—			(11		)	(142		)
Amounts reclassified from accumulated other comprehensive items	—			5			5			10

Net other comprehensive items	(131		)	5			(6		)	(132		)

Balance at June 29, 2019	$	(2,374	)	$	(47	)	$	(209	)	$	(2,630	)

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)


Note 12.	Fair Value Measurements and Fair Value of Financial Instruments

Fair Value Measurements

The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2019. The company’s financial assets and liabilities carried at fair value are primarily comprised of insurance contracts, investments in money market funds, derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration.

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.

Level 3: Inputs are unobservable data points that are not corroborated by market data.

The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of June 29, 2019 and December 31, 2018:



	June 29,		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In millions)	2019		(Level 1)		(Level 2)		(Level 3)

Assets
Cash equivalents	$	1,117	$	1,117	$	—	$	—
Investments in common stock, mutual funds and other similar instruments	20		20		—		—
Warrants	6		—		6		—
Insurance contracts	123		—		123		—
Derivative contracts	42		—		42		—

Total Assets	$	1,308	$	1,137	$	171	$	—

Liabilities
Derivative contracts	$	66	$	—	$	66	$	—
Contingent consideration	58		—		—		58

Total Liabilities	$	124	$	—	$	66	$	58

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)



	December 31,		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
(In millions)	2018		(Level 1)		(Level 2)		(Level 3)

Assets
Cash equivalents	$	769	$	769	$	—	$	—
Bank time deposits	2		2		—		—
Investments in mutual funds and other similar instruments	10		10		—		—
Warrants	8		—		8		—
Insurance contracts	113		—		113		—
Derivative contracts	31		—		31		—

Total Assets	$	933	$	781	$	152	$	—

Liabilities
Derivative contracts	$	145	$	—	$	145	$	—
Contingent consideration	37		—		—		37

Total Liabilities	$	182	$	—	$	145	$	37

The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company determines the fair value of acquisition-related contingent consideration based on the probability-weighted discounted cash flows associated with such future payments. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by level 3 inputs, of the contingent consideration.



	Three Months Ended						Six Months Ended
	June 29,			June 30,			June 29,			June 30,
(In millions)	2019			2018			2019			2018

Contingent Consideration
Beginning Balance	$	37		$	41		$	37		$	35
Acquisitions (including assumed balances)	24			—			24			11
Payments	—			—			—			(5		)
Change in fair value included in earnings	(3		)	(1		)	(3		)	(1		)

Ending Balance	$	58		$	40		$	58		$	40

Derivative Contracts

The following table provides the aggregate notional value of outstanding derivative contracts.



	June 29,		December 31,
(In millions)	2019		2018

Notional Amount
Interest rate swaps (described in Note 8)	$	3,100	$	3,100
Cross-currency interest rate swaps - designated as net investment hedges	1,800		1,500
Currency exchange contracts	3,642		3,424

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheet. The following tables present the fair value of derivative instruments in the consolidated balance sheet and statement of income.



	Fair Value – Assets				Fair Value – Liabilities
	June 29,		December 31,		June 29,		December 31,
(In millions)	2019		2018		2019		2018

Derivatives Designated as Hedging Instruments
Interest rate swaps (a)	$	—	$	—	$	46	$	129
Cross-currency interest rate swaps (b)	36		28		—		—
Derivatives Not Designated as Hedging Instruments
Currency exchange contracts (c)	6		3		20		16

Total Derivatives	$	42	$	31	$	66	$	145


(a)	The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities.


(b)	The fair value of the cross-currency interest rate swaps is included in the consolidated balance sheet under the caption other assets.


(c)	The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses.

The following amounts related to cumulative basis adjustments for fair value hedges were included in the consolidated balance sheet under the caption long-term obligations:



	Carrying Amount of the Hedged Liability				Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability (d)
	June 29,		December 31,		June 29,			December 31,
(In millions)	2019		2018		2019			2018

Long-term Obligations	$	3,368	$	3,291	$	(19	)	$	(93	)


(d)	Includes increases in the carrying amount of $24 million and $30 million at June 29, 2019 and December 31, 2018, respectively, on discontinued hedging relationships.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)



	Gain (Loss) Recognized
	Three Months Ended						Six Months Ended
	June 29,			June 30,			June 29,			June 30,
(In millions)	2019			2018			2019			2018

Fair Value Hedging Relationships
Interest rate swaps
Hedged long-term obligations - included in other expense, net	$	(53	)	$	10		$	(81	)	$	52
Derivatives designated as hedging instruments - included in other expense, net	54			(11		)	83			(49		)
Derivatives Designated as Cash Flow Hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to other expense, net	(4		)	(3		)	(7		)	(6		)
Derivatives Designated as Net Investment Hedges
Foreign currency-denominated debt
Included in currency translation adjustment within other comprehensive items	(97		)	400			59			200
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items	(30		)	3			7			3
Included in other expense, net	14			3			28			3
Derivatives Not Designated as Hedging Instruments
Currency exchange contracts
Included in cost of product revenues	(3		)	2			(1		)	—
Included in other expense, net	(11		)	35			6			27

Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the consolidated statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.

The company also uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The majority of the company’s euro-denominated senior notes and cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.

See Note 1 to the consolidated financial statements for 2018 included in the company's Annual Report on Form 10-K and Note 8 herein for additional information on the company's risk management objectives and strategies.

Fair Value of Other Financial Instruments

The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:



	June 29, 2019				December 31, 2018
	Carrying		Fair		Carrying		Fair
(In millions)	Value		Value		Value		Value

Debt Obligations:
Senior notes	$	18,283	$	19,313	$	18,276	$	18,322
Commercial paper	737		737		693		693
Other	20		20		21		21

	$	19,040	$	20,070	$	18,990	$	19,036

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

The fair value of debt obligations was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.


Note 13.	Supplemental Cash Flow Information



	Six Months Ended
	June 29,		June 30,
(In millions)	2019		2018

Non-cash Investing and Financing Activities
Declared but unpaid dividends	$	78	$	70
Issuance of stock upon vesting of restricted stock units	76		66

Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:



	June 29,		December 31,
(In millions)	2019		2018

Cash and Cash Equivalents	$	2,288	$	2,103
Restricted Cash Included in Other Current Assets	24		12
Restricted Cash Included in Other Assets	2		2

Cash, Cash Equivalents and Restricted Cash	$	2,314	$	2,117

Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.


Note 14.	Restructuring and Other Costs (Income), Net

Restructuring and other costs (income), net, in the first six months of 2019 primarily included the gain on the sale of the company's Anatomical Pathology business, and, to a lesser extent, transaction/integration costs related to acquisitions and a divestiture; sales of inventories revalued at the date of acquisition; and continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of operations within several facilities in the U.S. and Europe. In the first six months of 2019, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.

As of August 2, 2019, the company has identified restructuring actions that will result in additional charges of approximately $75 million, primarily in 2019 and 2020, and expects to identify additional actions during 2019 which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred.

During the second quarter of 2019, the company recorded net restructuring and other costs (income) by segment as follows:



(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs (Income), Net			Total

Life Sciences Solutions	$	5	$	—	$	8		$	13
Analytical Instruments	—		18		5			23
Specialty Diagnostics	—		—		(504		)	(504		)
Laboratory Products and Services	—		18		6			24
Corporate	—		—		1			1

	$	5	$	36	$	(484	)	$	(443	)

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

During the first six months of 2019, the company recorded net restructuring and other costs (income) by segment as follows:



(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs (Income), Net			Total

Life Sciences Solutions	$	11	$	—	$	11		$	22
Analytical Instruments	—		24		9			33
Specialty Diagnostics	—		4		(503		)	(499		)
Laboratory Products and Services	—		19		8			27
Corporate	—		—		2			2

	$	11	$	47	$	(473	)	$	(415	)

The principal components of net restructuring and other costs (income) by segment are as follows:

Life Sciences Solutions

In the first six months of 2019, the Life Sciences Solutions segment recorded $22 million of net restructuring and other costs, principally charges to cost of revenues of $11 million for the sales of inventory revalued at the date of acquisition. The segment also recorded $11 million of restructuring and other charges for the impairment of acquired technology in development, and severance and other costs associated with facility consolidations in the U.S. and Europe.

Analytical Instruments

In the first six months of 2019, the Analytical Instruments segment recorded $33 million of net restructuring and other charges, including $24 million of charges to selling, general, and administrative expense, principally transaction costs related to the acquisition of Gatan, subsequently terminated. The segment also recorded $9 million of restructuring and other costs, primarily for employee severance and other costs associated with facility consolidations in the U.S. and Europe.

Specialty Diagnostics

In the first six months of 2019, the Specialty Diagnostics segment recorded $499 million of net restructuring and other income, primarily a gain on the divestiture of its Anatomical Pathology business (see Note 2). The segment also recorded $4 million of charges to selling, general, and administrative expense for transaction costs in connection with the sale of the Anatomical Pathology business.

Laboratory Products and Services

In the first six months of 2019, the Laboratory Products and Services segment recorded $27 million of net restructuring and other charges. The segment recorded $19 million of charges to selling, general, and administrative expense, principally transaction costs related to the acquisition of Brammer Bio. The segment also recorded $8 million of restructuring and other costs, primarily for employee severance at businesses streamlining operations and employee compensation due at Brammer Bio on the date of acquisition.

Corporate

In the first six months of 2019, the company recorded $2 million of net restructuring and other costs for severance at its corporate operations.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(Unaudited)

The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs (income), net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.



(In millions)	Severance			Abandonment of Excess Facilities			Other (a)			Total

Balance at December 31, 2018	$	34		$	42		$	4		$	80
Cumulative effect of accounting change (b)	—			(28		)	—			(28		)
Costs incurred in 2019 (d)	13			3			7			23
Reserves reversed (c)	(1		)	(1		)	—			(2		)
Payments	(20		)	(7		)	(7		)	(34		)

Balance at June 29, 2019	$	26		$	9		$	4		$	39


(a)	Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.


(b)	Impact of adopting new lease accounting guidance on January 1, 2019.


(c)	Represents reductions in cost of plans.


(d)	Excludes $505 million gain on the sale of the company's Anatomical Pathology business; $6 million of impairment of acquired in-process research and development; $3 million of compensation due to employees on the date of acquisition; and $2 million of other non-cash charges, net.

The company expects to pay accrued restructuring costs primarily through 2019.

THERMO FISHER SCIENTIFIC INC.


Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 are made throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, earnings, margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, our liquidity position; cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that Thermo Fisher intends or believes will or may occur in the future. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers should not rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this Quarterly Report.

A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed under the heading "Risk Factors" in Part II, Item 1A of this report on Form 10-Q.

Overview

The company develops, manufactures and sells a broad range of products that are sold worldwide. The company expands the product lines and services it offers by developing and commercializing its own technologies and by making strategic acquisitions of complementary businesses. The company’s continuing operations fall into four business segments (see Note 4): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Services.

Recent Acquisitions and Divestiture

The company’s strategy is to augment internal growth at existing businesses with complementary acquisitions. The company’s principal recent acquisitions and divestitures are described below.

On October 25, 2018, the company acquired, within the Life Sciences Solutions segment, Becton Dickinson and Company's Advanced Bioprocessing business for $477 million in cash. This North America-based business adds complementary cell culture products that expand the segment's bioproduction offerings to help customers increase yield during production of biologic drugs. Revenues of the Advanced Bioprocessing business were $100 million in 2017.

On April 30, 2019, the company acquired, within the Laboratory Products and Services segment, Brammer Bio for approximately $1.7 billion in cash. Brammer Bio is a leading viral vector contract development and manufacturing organization for gene and cell therapies. The acquisition expands the segment's contract manufacturing capabilities. Revenues of Brammer Bio were approximately $140 million in 2018.

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Overview of Results of Operations and Liquidity



	Three Months Ended										Six Months Ended
	June 29,					June 30,					June 29,					June 30,
(Dollars in millions)	2019					2018					2019					2018

Revenues
Life Sciences Solutions	$	1,710		27.1	%	$	1,569		25.8	%	$	3,317		26.7	%	$	3,068		25.7	%
Analytical Instruments	1,324			21.0	%	1,311			21.6	%	2,646			21.3	%	2,568			21.5	%
Specialty Diagnostics	943			14.9	%	932			15.3	%	1,900			15.3	%	1,879			15.7	%
Laboratory Products and Services	2,633			41.7	%	2,550			42.0	%	5,146			41.4	%	4,963			41.6	%
Eliminations	(294		)	(4.7	)%	(284		)	(4.7	)%	(568		)	(4.7	)%	(547		)	(4.5	)%

	$	6,316		100	%	$	6,078		100	%	$	12,441		100	%	$	11,931		100	%

Sales in the second quarter of 2019 were $6.32 billion, an increase of $238 million from 2018. Sales increased $54 million due to acquisitions. The unfavorable effects of currency translation resulted in a decrease in revenues of $132 million in the second quarter of 2019. Aside from the effects of acquisitions and currency translation, revenues increased $316 million (5%) primarily due to increased demand in the quarter compared to the 2018 quarter. Sales to customers in each of the company's primary end markets grew except for sales to academic and government customers which were flat. Sales to customers in the biotech and pharmaceutical industry were particularly strong. Sales growth was strong in Asia and North America and moderate in Europe.

In the second quarter of 2019, total company operating income and operating income margin were $1.50 billion and 23.7%, respectively, compared with $0.94 billion and 15.4%, respectively, in 2018. The increase in operating income was primarily due to the gain on the sale of the Anatomical Pathology business and, to a lesser extent, profit on higher sales and productivity improvements, net of inflationary cost increases. These increases were offset in part by strategic growth investments, unfavorable foreign currency exchange and unfavorable sales mix. The company’s references to strategic growth investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, focused research projects and other expenditures to enhance the customer experience. The company’s references throughout this discussion to productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business system, reduced costs resulting from global sourcing initiatives, a lower cost structure following restructuring actions, including headcount reductions and consolidation of facilities, and low cost region manufacturing.

The company's effective tax rate was 19.7% for the second quarter of 2019. The second quarter 2019 provision for income taxes includes $187 million related to the gain on the sale of the Anatomical Pathology business and a tax provision of $28 million to adjust the impacts of U.S. tax reform based on final regulations issued by the U.S. Treasury in June 2019. In addition, in the second quarter of 2019, the company implemented foreign tax credit planning in Sweden which resulted in $75 million of foreign tax credits, with no related incremental U.S. income tax expense. The company expects its effective tax rate for all of 2019 will be between 8% and 11% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax expense for financial reporting purposes and are expected to total $725 to $775 million in 2019. The company's effective tax rate was 6.5% for the second quarter of 2018.

Net income increased to $1.12 billion in the second quarter of 2019 from $752 million in the second quarter of 2018, primarily due to the increase in operating income in the 2019 period (discussed above) offset in part by the increase in income taxes (discussed above).

During the first six months of 2019, the company’s cash flow from operations totaled $1.94 billion compared with $1.52 billion for 2018. The increase primarily resulted from lower investment in working capital in 2019.

As of June 29, 2019, the company’s short-term debt totaled $2.38 billion including $1.63 billion of senior notes due within the next twelve months and $0.74 billion of commercial paper obligations. The company has a revolving credit facility with a bank group that provides up to $2.50 billion of unsecured multi-currency revolving credit. If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of June 29, 2019, no borrowings were outstanding under the

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Overview of Results of Operations and Liquidity (continued)

company’s revolving credit facility, although available capacity was reduced by approximately $86 million as a result of outstanding letters of credit.

The company believes that its existing cash and cash equivalents of $2.29 billion as of June 29, 2019 and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.

Critical Accounting Policies and Estimates

The company’s discussion and analysis of its financial condition and results of operations is based upon its financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosure of contingent liabilities. On an on-going basis, management evaluates its estimates, including those related to intangible assets and goodwill, income taxes, contingencies and litigation, and pension costs. Management believes the most complex and sensitive judgments, because of their significance to the consolidated financial statements, result primarily from the need to make estimates about the effects of matters that are inherently uncertain. Management bases its estimates on historical experience, current market and economic conditions and other assumptions that management believes are reasonable. The results of these estimates form the basis for judgments about the carrying value of assets and liabilities where the values are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements of the company’s Form 10-K for 2018, describe the significant accounting estimates and policies used in preparation of the consolidated financial statements. While there have been no significant changes in the company's critical accounting policies during the first six months of 2019, as described in Note 1, the company changed the manner in which it accounts for leases under guidance that became effective January 1, 2019.

Results of Operations

Second Quarter 2019 Compared With Second Quarter 2018



	Three Months Ended
(In millions)	June 29, 2019			June 30, 2018			Total Change			Currency Translation			Acquisitions		Operations

Revenues
Life Sciences Solutions	$	1,710		$	1,569		$	141		$	(39	)	$	28	$	152
Analytical Instruments	1,324			1,311			13			(28		)	—		41
Specialty Diagnostics	943			932			11			(20		)	—		31
Laboratory Products and Services	2,633			2,550			83			(48		)	26		105
Eliminations	(294		)	(284		)	(10		)	3			—		(13		)

Consolidated Revenues	$	6,316		$	6,078		$	238		$	(132	)	$	54	$	316

Sales in the second quarter of 2019 were $6.32 billion, an increase of $238 million from the second quarter of 2018. Sales increased $54 million due to acquisitions. The unfavorable effects of currency translation resulted in a decrease in revenues of $132 million in 2019. Aside from the effects of acquisitions/divestitures and currency translation, revenues increased $316 million (5%) primarily due to increased demand in the quarter compared to the 2018 quarter. Sales to customers in each of the company's primary end markets grew except for sales to academic and government customers which were flat. Sales to customers in the biotech and pharmaceutical industry were particularly strong. Sales growth was strong in Asia and North America and moderate in Europe.

In the second quarter of 2019, the company recorded restructuring and other income, net, of $443 million, including $505 million of gain on the sale of the Anatomical Pathology business (see Note 2). The company recorded $5 million of charges to

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

cost of revenues primarily for the sale of inventories revalued at the date of acquisition. The company also recorded $36 million of charges to selling, general and administrative expenses, principally transaction costs related to acquisitions. In addition, the company recorded $11 million of cash restructuring charges, primarily for employee severance and abandoned facilities costs associated with the closure and consolidation of facilities in the U.S. and Europe. The company also recorded $6 million of charges for the impairment of acquired technology in development. See Note 14 for restructuring charges expected in future periods.

In the second quarter of 2018, the company recorded restructuring and other costs, net, of $25 million, including $5 million of charges to cost of revenues primarily for the sale of inventories revalued at the date of acquisition. The company recorded $3 million of charges to selling, general and administrative expenses, primarily transaction/integration costs related to the acquisition of Patheon. The company recorded $16 million of cash restructuring costs, including severance and abandoned facilities costs associated with the closure and consolidation of facilities in the U.S. and Europe. The company also recorded $1 million of other charges, net, principally for hurricane response costs.

Segment Results

The company’s management evaluates segment operating performance using operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition-related activities; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitate comparison of performance for determining compensation (Note 4). Accordingly, the following segment data is reported on this basis.



	Three Months Ended
	June 29,			June 30,
(Dollars in millions)	2019			2018			Change

Revenues
Life Sciences Solutions	$	1,710		$	1,569		9	%
Analytical Instruments	1,324			1,311			1	%
Specialty Diagnostics	943			932			1	%
Laboratory Products and Services	2,633			2,550			3	%
Eliminations	(294		)	(284		)	4	%

Consolidated Revenues	$	6,316		$	6,078		4	%

Segment Income
Life Sciences Solutions	$	609		$	522		17	%
Analytical Instruments	286			291			(2	)%
Specialty Diagnostics	242			253			(4	)%
Laboratory Products and Services	345			337			2	%

Subtotal Reportable Segments	1,482			1,403			6	%

Cost of Revenues Charges, Net	(5		)	(5		)
Selling, General and Administrative Charges, Net	(36		)	(3		)
Restructuring and Other (Income) Costs, Net	484			(17		)
Amortization of Acquisition-related Intangible Assets	(429		)	(441		)

Consolidated Operating Income	$	1,496		$	937		60	%

Reportable Segments Operating Income Margin	23.5		%	23.1		%

Consolidated Operating Income Margin	23.7		%	15.4		%

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

Income from the company’s reportable segments increased 6% to $1.48 billion in the second quarter of 2019 due primarily to profit on higher sales and, to a lesser extent, productivity improvements, net of inflationary cost increases, offset in part by strategic growth investments, unfavorable foreign currency exchange and unfavorable sales mix.

Life Sciences Solutions



	Three Months Ended
	June 29,			June 30,
(Dollars in millions)	2019			2018			Change

Revenues	$	1,710		$	1,569		9	%

Operating Income Margin	35.6		%	33.3		%	2.3 pt

Sales in the Life Sciences Solutions segment increased $141 million to $1.71 billion in the second quarter of 2019. Sales increased $152 million (10%) due to higher revenues at existing businesses and $28 million due to an acquisition. The unfavorable effects of currency translation resulted in a decrease in revenues of $39 million. The increase in revenue at existing businesses was primarily due to increased demand in each of the segment's principal businesses with particular strength in sales of bioproduction and biosciences products.

Operating income margin was 35.6% in the second quarter of 2019 compared to 33.3% in the second quarter of 2018. The increase resulted primarily from profit on higher sales and, to a lesser extent, productivity improvements, net of inflationary cost increases, offset in part by strategic growth investments and, to a lesser extent, unfavorable sales mix and unfavorable foreign currency exchange.

Analytical Instruments



	Three Months Ended
	June 29,			June 30,
(Dollars in millions)	2019			2018			Change

Revenues	$	1,324		$	1,311		1	%

Operating Income Margin	21.6		%	22.2		%	-0.6 pt

Sales in the Analytical Instruments segment increased $13 million to $1.32 billion in the second quarter of 2019. Sales increased $41 million (3%) due to higher revenues at existing businesses. The unfavorable effects of currency translation resulted in a decrease in revenues of $28 million. The increase in revenue at existing businesses was due to increased demand for chromatography and mass spectrometry products as well as chemical analysis products.

Operating income margin was 21.6% in the second quarter of 2019 compared to 22.2% in the second quarter of 2018. The decrease resulted primarily from unfavorable sales mix, strategic growth investments and, to a lesser extent, unfavorable foreign currency exchange, offset in part by profit on higher sales and, to a lesser extent, productivity improvements, net of inflationary cost increases.

Specialty Diagnostics



	Three Months Ended
	June 29,			June 30,
(Dollars in millions)	2019			2018			Change

Revenues	$	943		$	932		1	%

Operating Income Margin	25.7		%	27.2		%	-1.5 pt

Sales in the Specialty Diagnostics segment increased $11 million to $943 million in the second quarter of 2019. Sales increased $31 million (3%) due to higher revenues at existing businesses. The unfavorable effects of currency translation resulted in a decrease in revenues of $20 million. The increase in revenue at existing businesses was due to higher demand for

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

products sold through the segment's healthcare market channel business and for clinical diagnostic products and immunodiagnostic products. These increases were offset in part by lower sales in the Anatomical Pathology business, which the company sold at the end of the quarter.

Operating income margin was 25.7% in the second quarter of 2019 and 27.2% in the second quarter of 2018. The decrease was primarily due to weaker performance at the segment's former Anatomical Pathology business as well as strategic growth investments and unfavorable sales mix, offset in part by productivity improvements, net of inflationary cost increases, and profit on higher sales.

Laboratory Products and Services



	Three Months Ended
	June 29,			June 30,
(Dollars in millions)	2019			2018			Change

Revenues	$	2,633		$	2,550		3	%

Operating Income Margin	13.1		%	13.2		%	-0.1 pt

Sales in the Laboratory Products and Services segment increased $83 million to $2.63 billion in the second quarter of 2019. Sales increased $105 million (4%) due to higher revenues at existing businesses and $26 million due to an acquisition. The unfavorable effects of currency translation resulted in a decrease in revenues of $48 million. The increase in revenue at existing businesses was primarily due to increased demand for service offerings of the segment's pharma services business and products sold through its research and safety market channel business.

Operating income margin was 13.1% in the second quarter of 2019 and 13.2% in the second quarter of 2018. The decrease was primarily due to strategic growth investments and unfavorable sales mix offset in part by productivity improvements, net of inflationary cost increases, and profit on higher sales.

Other Expense, Net

The company reported other expense, net, of $103 million and $131 million in the second quarter of 2019 and 2018, respectively (Note 5). An increase in interest income of $29 million in 2019 was offset in part by an increase in interest expense of $11 million.

Provision for Income Taxes

The company has operations and a taxable presence in approximately 50 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income, aside from any resulting one-time adjustment to the company’s deferred tax balances to reflect a new rate.

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

First Six Months of 2019 Compared With First Six Months of 2018



	Six Months Ended
(In millions)	June 29, 2019			June 30, 2018			Total Change			Currency Translation			Acquisitions		Operations

Revenues
Life Sciences Solutions	$	3,317		$	3,068		$	249		$	(87	)	$	59	$	277
Analytical Instruments	2,646			2,568			78			(66		)	—		144
Specialty Diagnostics	1,900			1,879			21			(47		)	—		68
Laboratory Products and Services	5,146			4,963			183			(120		)	26		277
Eliminations	(568		)	(547		)	(21		)	8			—		(29		)

Consolidated Revenues	$	12,441		$	11,931		$	510		$	(312	)	$	85	$	737

Sales in the first six months of 2019 were $12.44 billion, an increase of $510 million from the first six months of 2018. Sales increased $85 million due to acquisitions. The unfavorable effects of currency translation resulted in a decrease in revenues of $312 million in 2019. Aside from the effects of currency translation and acquisitions, revenues increased $737 million (6%) primarily due to increased demand. Sales to customers in each of the company's primary end markets grew with particular strength in sales to customers in the biotech and pharmaceutical industry. Sales growth was strong in each of the company's primary geographic areas, particularly Asia.

In the first six months of 2019, total company operating income and operating income margin were $2.42 billion and 19.4%, respectively, compared with $1.72 billion and 14.4%, respectively, in the first six months of 2018. The increase in operating income was primarily due to the gain on the sale of the Anatomical Pathology business, profit on higher sales and, to a lesser extent, productivity improvements, net of inflationary cost increases. These increases were offset in part by strategic growth investments, unfavorable foreign currency exchange and unfavorable sales mix.

In the first six months of 2019, the company recorded restructuring and other income, net, of $415 million, including $505 million of gain on the sale of the Anatomical Pathology business (see Note 2). The company also recorded $11 million of charges to cost of revenues primarily for the sale of inventories revalued at the date of acquisition, and $47 million of net charges to selling, general and administrative expenses, principally transaction costs related to acquisitions and a divestiture. In addition, the company recorded $21 million of cash restructuring charges, net, primarily for employee severance and abandoned facilities costs associated with the closure and consolidation of facilities in the U.S. and Europe (see Note 14).

In the first six months of 2018, the company recorded restructuring and other costs, net, of $81 million, including $8 million of charges to cost of revenues primarily for the sale of inventories revalued at the date of acquisition. The company recorded $11 million of charges to selling, general and administrative expenses, primarily for transaction and integration costs associated with recent acquisitions and changes in estimates of acquisition contingent consideration. In addition, the company recorded $51 million of cash restructuring costs in its continuing effort to streamline operations, including severance at several businesses and abandoned facility expenses at businesses that have been or are being consolidated in the U.S., Europe and Asia. The company also recorded $11 million of other costs, net, principally charges for litigation-related matters, and hurricane response costs.

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

Segment Results



	Six Months Ended
	June 29,			June 30,
(Dollars in millions)	2019			2018			Change

Revenues
Life Sciences Solutions	$	3,317		$	3,068		8	%
Analytical Instruments	2,646			2,568			3	%
Specialty Diagnostics	1,900			1,879			1	%
Laboratory Products and Services	5,146			4,963			4	%
Eliminations	(568		)	(547		)	4	%

Consolidated Revenues	$	12,441		$	11,931		4	%

Segment Income
Life Sciences Solutions	$	1,170		$	1,039		13	%
Analytical Instruments	568			537			6	%
Specialty Diagnostics	484			496			(2	)%
Laboratory Products and Services	630			617			2	%

Subtotal Reportable Segments	2,852			2,689			6	%

Cost of Revenues Charges	(11		)	(8		)
Selling, General and Administrative Charges, Net	(47		)	(11		)
Restructuring and Other Income (Costs), Net	473			(62		)
Amortization of Acquisition-related Intangible Assets	(851		)	(885		)

Consolidated Operating Income	$	2,416		$	1,723		40	%

Reportable Segments Operating Income Margin	22.9		%	22.5		%

Consolidated Operating Income Margin	19.4		%	14.4		%

Income from the company’s reportable segments increased 6% to $2.85 billion in the first six months of 2019 due primarily to profit on higher sales and, to a lesser extent, productivity improvements, net of inflationary cost increases, offset in part by strategic growth investments, unfavorable foreign currency exchange and unfavorable sales mix.

Life Sciences Solutions



	Six Months Ended
	June 29,			June 30,
(Dollars in millions)	2019			2018			Change

Revenues	$	3,317		$	3,068		8	%

Operating Income Margin	35.3		%	33.9		%	1.4 pt

Sales in the Life Sciences Solutions segment increased $249 million to $3.32 billion in the first six months of 2019. Sales increased $277 million (9%) due to higher revenues at existing businesses and $59 million due to an acquisition. The unfavorable effects of currency translation resulted in a decrease in revenues of $87 million. The increase in revenue at existing businesses was primarily due to increased demand in each of the segment's principal businesses with particular strength in sales of bioproduction and biosciences products.

Operating income margin was 35.3% in the first six months of 2019 compared to 33.9% in the first six months of 2018. The increase resulted primarily from profit on higher sales and, to a lesser extent, productivity improvements, net of

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

inflationary cost increases, offset in part by strategic growth investments, unfavorable sales mix and, to a lesser extent, unfavorable foreign currency exchange.

Analytical Instruments



	Six Months Ended
	June 29,			June 30,
(Dollars in millions)	2019			2018			Change

Revenues	$	2,646		$	2,568		3	%

Operating Income Margin	21.4		%	20.9		%	0.5 pt

Sales in the Analytical Instruments segment increased $78 million to $2.65 billion in the first six months of 2019. Sales increased $144 million (6%) due to higher revenues at existing businesses. The unfavorable effects of currency translation resulted in a decrease in revenues of $66 million. The increase in revenue at existing businesses was due to increased demand for products sold by each of the segment's primary businesses with particular strength in chromatography and mass spectrometry instruments and chemical analysis instruments.

Operating income margin was 21.4% in the first six months of 2019 compared to 20.9% in the first six months of 2018. The increase resulted primarily from profit on higher sales and, to a lesser extent, productivity improvements, net of inflationary cost increases. These increases were offset in part by unfavorable sales mix and strategic growth investments.

Specialty Diagnostics



	Six Months Ended
	June 29,			June 30,
(Dollars in millions)	2019			2018			Change

Revenues	$	1,900		$	1,879		1	%

Operating Income Margin	25.5		%	26.4		%	-0.9 pt

Sales in the Specialty Diagnostics segment increased $21 million to $1.90 billion in the first six months of 2019. Sales increased $68 million (4%) due to higher revenues at existing businesses. The unfavorable effects of currency translation resulted in a decrease in revenues of $47 million. The increase in revenue at existing businesses was due to higher demand for clinical diagnostic products and immunodiagnostic products as well as products sold through the segment's healthcare market channel business.

Operating income margin was 25.5% in the first six months of 2019 compared to 26.4% in the first six months of 2018. The decrease was primarily due to strategic growth investments offset in part by profit on higher sales and, to a lesser extent, productivity improvements, net of inflationary cost increases.

Laboratory Products and Services



	Six Months Ended
	June 29,			June 30,
(Dollars in millions)	2019			2018			Change

Revenues	$	5,146		$	4,963		4	%

Operating Income Margin	12.2		%	12.4		%	-0.2 pt

Sales in the Laboratory Products and Services segment increased $183 million to $5.15 billion in 2019. Sales increased $277 million (6%) due to higher revenues at existing businesses and $26 million due to acquisitions. The unfavorable effects of currency translation resulted in a decrease in revenues of $120 million. The increase in revenue at existing businesses was primarily due to increased demand in each of the segment's principal businesses with particular strength in service offerings of its pharma services business and products sold through its research and safety market channel business.

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Results of Operations (continued)

Operating income margin was 12.2% in the first six months of 2019 compared to 12.4% in the first six months of 2018. The decrease was primarily due to strategic growth investments and unfavorable sales mix offset in part by productivity improvements, net of inflationary cost increases, and profit on higher sales.

Other Expense, Net

The company reported other expense, net, of $206 million and $283 million in the first six months of 2019 and 2018, respectively (Note 5). An increase in interest income of $76 million was offset in part by an increase in interest expense of $37 million.

Provision for Income Taxes

The company recorded a $276 million provision for income taxes in the first six months of 2019 including $187 million related to the gain on the sale of the Anatomical Pathology business. In addition, in 2019, the company recorded a $62 million income tax benefit related to a foreign exchange loss for tax purposes on certain intercompany financing arrangements and implemented foreign tax credit planning in Sweden which resulted in $75 million of foreign tax credits, with no related incremental U.S. income tax expense.

The company recorded a $109 million provision for income taxes in the first six months of 2018. In the first quarter of 2018, the company recorded a net tax provision of $21 million to adjust the estimated initial impacts of U.S. tax reform recorded in 2017, consisting of an incremental provision of $70 million offset in part by a $49 million reduction of related unrecognized tax benefits established in 2017. The adjustment was required based on new U.S. Treasury guidance released in the first quarter of 2018.

Recent Accounting Pronouncements

A description of recently issued accounting standards is included under the heading "Recent Accounting Pronouncements" in Note 1.

Contingent Liabilities

The company is contingently liable with respect to certain legal proceedings and related matters. An unfavorable outcome that differs materially from current accrual estimates, if any, for one or more of the matters described under the headings "Product Liability, Workers Compensation and Other Personal Injury Matters," "Intellectual Property Matters" and "Commercial Matters" in Note 10 could have a material adverse effect on the company’s financial position as well as its results of operations and cash flows.

Liquidity and Capital Resources

Consolidated working capital (current assets less current liabilities) was $3.71 billion at June 29, 2019, compared with $4.48 billion at December 31, 2018. The decrease resulted primarily from an increase in short-term debt. Included in working capital were cash and cash equivalents of $2.29 billion at June 29, 2019 and $2.10 billion at December 31, 2018.

First Six Months of 2019

Cash provided by operating activities was $1.94 billion during the first six months of 2019. Cash provided by income was offset in part by investments in working capital. Increases in inventories used cash of $273 million primarily to support growth in sales. An increase in other assets used cash of $179 million primarily due to the timing of customer billings. Other liabilities increased by $319 million primarily due to advance payments from customers. Cash payments for income taxes decreased to $417 million during the first six months of 2019, compared with $458 million in the first six months of 2018. The company made cash contributions to its pension and postretirement benefit plans totaling $34 million during the first six months of 2019. Payments for restructuring actions, principally severance costs and lease and other expenses of real estate consolidation, used cash of $34 million during the first six months of 2019.

During the first six months of 2019, the company’s investing activities used $950 million of cash. Acquisitions used cash of $1.69 billion. Proceeds from the sale of the Anatomical Pathology business provided $1.13 billion. The company's investing activities also included the purchase of $421 million of property, plant and equipment.

The company’s financing activities used $735 million of cash during the first six months of 2019. The company’s financing activities included the repurchase of $750 million of the company's common stock and the payment of $144 million in cash dividends, offset in part by $122 million of net proceeds from employee stock option exercises. A net increase in commercial paper obligations provided cash of $40 million. On September 7, 2018, the Board of Directors authorized the repurchase of up

THERMO FISHER SCIENTIFIC INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS

Liquidity and Capital Resources (continued)

to $2.00 billion of the company’s common stock. At August 2, 2019, authorization remained for $1.25 billion of future repurchases of the company’s common stock. On July 24, 2019, the company repaid its €500 million Floating Rate Senior Note with cash on hand.

The company's commitments for purchases of property, plant and equipment, contractual obligations and other commercial commitments did not change materially between December 31, 2018 and June 29, 2019 except for an agreement to acquire a drug substance manufacturing site in Cork, Ireland for approximately €90 million in cash plus approximately €50 million of inventories at the site. The company expects that for all of 2019, expenditures for property, plant and equipment, net of disposals, will approximate $925 and $975 million.

Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs outside of the U.S. including acquisitions and repayment of acquisition-related intercompany debt to the U.S. In addition, the company also transfers cash to the U.S. using non-taxable returns of capital as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.

First Six Months of 2018

Cash provided by operating activities was $1.52 billion during the first six months of 2018. Cash provided by income was offset in part by investments in working capital. Increases in accounts receivable and inventories used cash of $97 million and $195 million, respectively, primarily to support growth in sales. An increase in other assets used cash of $296 million primarily due to the timing of customer billings and income tax refunds. Other liabilities decreased by $359 million primarily due to the timing of payments for incentive compensation and income taxes. Cash payments for income taxes totaled $458 million. The company made cash contributions to its pension and postretirement benefit plans totaling $43 million during the first six months of 2018. Payments for restructuring actions, principally severance costs and lease and other expenses of real estate consolidation, used cash of $46 million during the first six months of 2018.

During the first six months of 2018, the company’s investing activities used $364 million of cash. Acquisitions used cash of $59 million. The company’s investing activities also included the purchase of $301 million of property, plant and equipment.

The company’s financing activities used $1.35 billion of cash during the first six months of 2018. Repayment of senior notes used cash of $1.35 billion. A net increase in commercial paper obligations provided cash of $106 million. The company’s financing activities also included the payment of $129 million in cash dividends, offset in part by $78 million of net proceeds from employee stock option exercises.


Item 3.	Quantitative and Qualitative Disclosures About Market Risk

The company's exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure at year-end 2018.

THERMO FISHER SCIENTIFIC INC.


Item 4.	Controls and Procedures

Management’s Evaluation of Disclosure Controls and Procedures

The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the company’s disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended June 29, 2019, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.


PART II	OTHER INFORMATION


Item 1.	Legal Proceedings

There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See "Note 10 to our Consolidated Financial Statements – Commitments and Contingencies."


Item 1A.	Risk Factors

Set forth below are the risks that we believe are material to our investors. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements beginning on page 29.

We must develop new products, adapt to rapid and significant technological change and respond to introductions of new products by competitors to remain competitive. Our growth strategy includes significant investment in and expenditures for product development. We sell our products in several industries that are characterized by rapid and significant technological changes, frequent new product and service introductions and enhancements and evolving industry standards. Competitive factors include technological innovation, price, service and delivery, breadth of product line, customer support, e-business capabilities and the ability to meet the special requirements of customers. Our competitors may adapt more quickly to new technologies and changes in customers’ requirements than we can. Without the timely introduction of new products, services and enhancements, our products and services will likely become technologically obsolete over time, in which case our revenue and operating results would suffer.

Many of our existing products and those under development are technologically innovative and require significant planning, design, development and testing at the technological, product and manufacturing-process levels. Our customers use many of our products to develop, test and manufacture their own products. As a result, we must anticipate industry trends and develop products in advance of the commercialization of our customers’ products. If we fail to adequately predict our customers’ needs and future activities, we may invest heavily in research and development of products and services that do not lead to significant revenue.

It may be difficult for us to implement our strategies for improving internal growth. Our growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets could diminish demand for our products and services, which would adversely affect our results of operations and financial condition. To address this issue, we are pursuing a number of strategies to improve our internal growth, including:


•	strengthening our presence in selected geographic markets;


•	allocating research and development funding to products with higher growth prospects;


•	developing new applications for our technologies;


•	expanding our service offerings;


•	continuing key customer initiatives;


•	combining sales and marketing operations in appropriate markets to compete more effectively;

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)


•	finding new markets for our products; and


•	continuing the development of commercial tools and infrastructure to increase and support cross-selling opportunities of products and services to take advantage of our depth in product offerings.

We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.

Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate. Our business is affected by general economic conditions, both inside and outside the U.S. If the global economy and financial markets, or economic conditions in Europe, the U.S. or other key markets, are unstable, it could adversely affect the business, results of operations and financial condition of the company and its customers, distributors, and suppliers, having the effect of


•	reducing demand for some of our products;


•	increasing the rate of order cancellations or delays;


•	increasing the risk of excess and obsolete inventories;


•	increasing pressure on the prices for our products and services;


•	causing supply interruptions which could disrupt our ability to produce our products; and


•	creating longer sales cycles and greater difficulty in collecting sales proceeds.

Demand for some of our products depends on capital spending policies of our customers and on government funding policies. Our customers include pharmaceutical and chemical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions. Many factors, including public policy spending priorities, available resources and product and economic cycles, have a significant effect on the capital spending policies of these entities.

Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal budget. An impasse in federal government budget decisions could lead to substantial delays or reductions in federal spending.

Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations. International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in currencies other than the one in which they primarily do business (the "functional currency"). Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In the first six months of 2019, currency translation had an unfavorable effect of $312 million on revenues due to the strengthening of the U.S. dollar relative to other currencies in which the company sells products and services.

In addition, many of our employees, contract manufacturers, suppliers, job functions, outsourcing activities and manufacturing facilities are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:


•	interruption to transportation flows for delivery of parts to us and finished goods to our customers;


•	changes in a specific country's or region's political, economic or other conditions;


•	changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes and sanctions and other trade barriers;


•	tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs recently adopted by the U.S. government on various imports from China and by the Chinese government on certain U.S. goods;


•	negative consequences from changes in tax laws;


•	difficulty in staffing and managing widespread operations;

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)


•	differing labor regulations;


•	differing protection of intellectual property;


•	unexpected changes in regulatory requirements; and


•	geopolitical uncertainty or turmoil, including terrorism and war.

Significant developments stemming from the U.S. administration or the U.K.’s referendum on membership in the EU could have an adverse effect on us. The U.S. administration has called for substantial changes to trade agreements and is imposing significant increases on tariffs on goods imported into the United States. The administration has also indicated an intention to request Congress to make significant changes, replacement or elimination of the Patient Protection and Affordable Care Act, and government negotiation/regulation of drug prices paid by government programs. Changes in U.S. social, political, regulatory and economic conditions or laws and policies governing the health care system and drug prices, foreign trade, manufacturing, and development and investment in the territories and countries where we or our customers operate could adversely affect our operating results and our business.

Additionally, on June 23, 2016, the United Kingdom held a referendum and voted in favor of leaving the European Union, or EU. This referendum has created political and economic uncertainty, particularly in the United Kingdom and the EU, and this uncertainty may last for years. Our business could be affected during this period of uncertainty, and perhaps longer, by the impact of the United Kingdom’s referendum. In addition, our business could be negatively affected by new trade agreements between the United Kingdom and other countries, including the United States, and by the possible imposition of trade or other regulatory barriers in the United Kingdom. These possible negative impacts, and others resulting from the United Kingdom’s actual or threatened withdrawal from the EU, may adversely affect our operating results and our customers’ businesses.

Our inability to protect our intellectual property could have a material adverse effect on our business. In addition, third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result. We place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes because of the length of time and expense associated with bringing new products through the development process and into the marketplace. Our success depends in part on our ability to develop patentable products and obtain and enforce patent protection for our products both in the United States and in other countries. We own numerous U.S. and foreign patents, and we intend to file additional applications, as appropriate, for patents covering our products. Patents may not be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology. Any issued patents owned by or licensed to us may be challenged, invalidated or circumvented, and the rights under these patents may not provide us with competitive advantages. In addition, competitors may design around our technology or develop competing technologies. Intellectual property rights may also be unavailable or limited in some foreign countries, which could make it easier for competitors to capture increased market position. We could incur substantial costs to defend ourselves in suits brought against us or in suits in which we may assert our patent rights against others. An unfavorable outcome of any such litigation could materially adversely affect our business and results of operations.

We also rely on trade secrets and proprietary know-how with which we seek to protect our products, in part, by confidentiality agreements with our collaborators, employees and consultants. These agreements may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently developed by our competitors.

Third parties may assert claims against us to the effect that we are infringing on their intellectual property rights. In the event that a claim relating to intellectual property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may seek licenses to such intellectual property or challenge those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at all, and our challenge of the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture, or distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.

Changes in governmental regulations may reduce demand for our products or increase our expenses. We compete in many markets in which we and our customers must comply with federal, state, local and international regulations, such as environmental, health and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by those regulations. Any significant change in regulations could reduce demand for our products or increase our expenses. For example, many of our instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs. Changes in the U.S. Food and Drug Administration’s regulation of the drug discovery and development process could have an adverse effect on the demand for these products.

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)

Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could suffer. Our pharma services offerings are highly exacting and complex, due in part to strict quality and regulatory requirements. Our operating results in this business depend on our ability to execute and, when necessary, improve our quality management strategy and systems, and our ability to effectively train and maintain our employee base with respect to quality management. A failure of our quality control systems could result in problems with facility operations or preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations. Such problems could affect production of a particular batch or series of batches of products, requiring the destruction of such products or a halt of facility production altogether.

In addition, our failure to meet required quality standards may result in our failure to timely deliver products to our customers, which in turn could damage our reputation for quality and service. Any such failure could, among other things, lead to increased costs, lost revenue, reimbursement to customers for lost drug product, registered intermediates, registered starting materials, and active pharmaceutical ingredients, other customer claims, damage to and possibly termination of existing customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. Production problems in our drug and biologic manufacturing operations could be particularly significant because the cost of raw materials for such manufacturing is often high. If problems in preparation or manufacture of a product or failures to meet required quality standards for that product are not discovered before such product is released to the market, we may be subject to adverse regulatory actions, including product recalls, product seizures, injunctions to halt manufacture and distribution, restrictions on our operations, civil sanctions, including monetary sanctions, and criminal actions. In addition, such problems or failures could subject us to litigation claims, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant.

We are subject to product and other liability risks for which we may not have adequate insurance coverage. We may be named as a defendant in product liability lawsuits, which may allege that products or services we have provided from our pharma services offerings have resulted or could result in an unsafe condition or injury to consumers. Additionally, products currently or previously sold by our environmental and process instruments and radiation measurement and security instruments businesses include fixed and portable instruments used for chemical, radiation and trace explosives detection. These products are used in airports, embassies, cargo facilities, border crossings and other high-threat facilities for the detection and prevention of terrorist acts. If any of these products were to malfunction, it is possible that explosive or radioactive material could fail to be detected by our product, which could lead to product liability claims. There are also many other factors beyond our control that could lead to liability claims, such as the reliability and competence of the customers’ operators and the training of such operators.

Any such product liability claims brought against us could be significant and any adverse determination may result in liabilities in excess of our insurance coverage. Although we carry product liability insurance, we cannot be certain that our current insurance will be sufficient to cover these claims or that it can be maintained on acceptable terms, if at all.

Our inability to complete any pending acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect on our business. Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services. Certain acquisitions may be difficult to complete for a number of reasons, including the need for antitrust and/or other regulatory approvals. Any acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets of the acquired company. Further, we may not be able to integrate acquired businesses successfully into our existing businesses, make such businesses profitable, or realize anticipated cost savings or synergies, if any, from these acquisitions, which could adversely affect our business.

Moreover, we have acquired many companies and businesses. As a result of these acquisitions, we recorded significant goodwill and indefinite-lived intangible assets (primarily tradenames) on our balance sheet, which amount to approximately $25.76 billion and $1.25 billion, respectively, as of June 29, 2019. In addition, we have definite-lived intangible assets totaling $13.61 billion as of June 29, 2019. We assess the realizability of goodwill and indefinite-lived intangible assets annually as well as whenever events or changes in circumstances indicate that these assets may be impaired. We assess the realizability of definite-lived intangible assets whenever events or changes in circumstances indicate that these assets may be impaired. These events or circumstances would generally include operating losses or a significant decline in earnings associated with the acquired business or asset. Our ability to realize the value of the goodwill and intangible assets will depend on the future cash flows of these businesses. These cash flows in turn depend in part on how well we have integrated these businesses. If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the impairment of those assets.

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)

We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by leading to a reduction in revenue associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

Because we compete directly with certain of our larger customers and product suppliers, our results of operations could be adversely affected in the short term if these customers or suppliers abruptly discontinue or significantly modify their relationship with us. Our largest customer in the laboratory products business is also a significant competitor. Our business may be harmed in the short term if our competitive relationship in the marketplace with certain of our large customers results in a discontinuation of their purchases from us. In addition, we manufacture products that compete directly with products that we source from third-party suppliers. We also source competitive products from multiple suppliers. Our business could be adversely affected in the short term if any of our large third-party suppliers abruptly discontinues selling products to us.

Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability. We ship a significant portion of our products to our customers through independent package delivery companies, such as Federal Express in the U.S. and DHL in Europe. We also maintain a small fleet of vehicles dedicated to the delivery of our products and ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S. Postal Service. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.

We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies. We are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the U.S. Federal Drug Administration (the FDA), the U.S. Drug Enforcement Agency (the DEA), various state boards of pharmacy, state health departments, the U.S. Department of Health and Human Services (the DHHS), the European Medicines Agency (the EMA), in Europe, the EU member states and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices and drug safety. Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of the DEA, the FDA, the DHHS, foreign agencies including the EMA, and other various state boards of pharmacy, state health departments and/or comparable state agencies as well as certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale.

The manufacture, distribution and marketing of many of our products and services, including medical devices and pharma services, are subject to extensive ongoing regulation by the FDA, the DEA, the EMA, and other equivalent local, state, federal and non-U.S. regulatory authorities. In addition, we are subject to inspections by these regulatory authorities. Failure by us or by our customers to comply with the requirements of these regulatory authorities, including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could expose us to contractual or product liability claims, contractual claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are the sole manufacturer of a number of pharmaceuticals for many of our customers and a negative regulatory event could impact our customers' ability to provide products to their customers.

We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the importation and exportation of products, the handling, transportation and manufacture of substances that could be classified as hazardous, and our business practices in the U.S. and abroad such as anti-corruption, anti-competition and privacy and data protection laws. Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)

obtain necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of operations.

Our business could be adversely affected by disruptions at our sites. We rely upon our manufacturing operations to produce many of the products we sell and our warehouse facilities to store products, pending sale. Any significant disruption of those operations for any reason, such as strikes or other labor unrest, power interruptions, fire, hurricanes or other events beyond our control could adversely affect our sales and customer relationships and therefore adversely affect our business. We have significant operations in California, near major earthquake faults, which make us susceptible to earthquake risk. Although most of our raw materials are available from a number of potential suppliers, our operations also depend upon our ability to obtain raw materials at reasonable prices. If we are unable to obtain the materials we need at a reasonable price, we may not be able to produce certain of our products or we may not be able to produce certain of these products at a marketable price, which could have an adverse effect on our results of operations.

Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows. As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. In preparing our financial statements, we record the amount of tax that is payable in each of the countries, states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash flows.

We may incur unexpected costs from increases in fuel and raw material prices, which could reduce our earnings and cash flow. Our primary commodity exposures are for fuel, petroleum-based resins and steel. While we may seek to minimize the impact of price increases through higher prices to customers and various cost-saving measures, our earnings and cash flows could be adversely affected in the event these measures are insufficient to cover our costs.

A significant disruption in, or breach in security of, our information technology systems or violation of data privacy laws could adversely affect our business. As a part of our ongoing effort to upgrade our current information systems, we periodically implement new enterprise resource planning software and other software applications to manage certain of our business operations. As we implement and add functionality, problems could arise that we have not foreseen. Such problems could disrupt our ability to provide quotes, take customer orders and otherwise run our business in a timely manner. When we upgrade or change systems, we may suffer interruptions in service, loss of data or reduced functionality. In addition, if our new systems fail to provide accurate pricing and cost data our results of operations and cash flows could be adversely affected.

We also rely on our information technology systems to process, transmit and store electronic information (including sensitive data such as confidential business information and personally identifiable data relating to employees, customers and other business partners) and to manage or support a variety of critical business processes and activities (such as interacting with suppliers, selling our products and services, fulfilling orders and billing, collecting and making payments, shipping products, providing services and support to customers, tracking customer activity, fulfilling contractual obligations and otherwise conducting business). Our systems may be vulnerable to damage or interruption from natural disasters, power loss, telecommunication failures, terrorist attacks, computer hackers, computer viruses, ransomware, phishing, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite any precautions we may take, such problems could result in, among other consequences, interruptions in our services, which could harm our reputation and financial results. Any of the cyber-attacks, breaches or other disruptions or damage described above, if significant, could materially interrupt our operations, delay production and shipments, result in theft of our and our customers’ intellectual property and trade secrets, damage customer, business partner and employee relationships and our reputation or result in defective products or services, legal claims and proceedings, liability and penalties under privacy laws and increased cost for security and remediation, each of which could adversely affect our business and financial results.

If we are unable to maintain reliable information technology systems and appropriate controls with respect to global data privacy and security requirements and prevent data breaches, we may suffer regulatory consequences in addition to business consequences. As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business. For example, in the United States, individual states regulate data breach and security requirements and multiple governmental bodies assert authority over aspects of the protection of personal privacy. European laws require us to have an approved legal mechanism to transfer personal data out of Europe, and the recently-enacted EU General Data Protection Regulation, which took effect in May 2018, imposes significantly stricter requirements in how we collect and

THERMO FISHER SCIENTIFIC INC.

Risk Factors (continued)

process personal data. Several countries, such as China and Russia, have passed laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions. Government enforcement actions can be costly and interrupt the regular operation of our business, and data breaches or violations of data privacy laws can result in fines, reputational damage and civil lawsuits, any of which may adversely affect our business, reputation and financial statements.

Our debt may restrict our investment opportunities or limit our activities. As of June 29, 2019, we had approximately $19.04 billion in outstanding indebtedness. In addition, we have availability to borrow under a revolving credit facility that provides for up to $2.50 billion of unsecured multi-currency revolving credit. We may also obtain additional long-term debt and lines of credit to meet future financing needs, which would have the effect of increasing our total leverage.

Our leverage could have negative consequences, including increasing our vulnerability to adverse economic and industry conditions, limiting our ability to obtain additional financing and limiting our ability to acquire new products and technologies through strategic acquisitions.

Our ability to make scheduled payments, refinance our obligations or obtain additional financing will depend on our future operating performance and on economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flow to meet our obligations. If we are unable to service our debt, refinance our existing debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures or research and development expenditures.

Additionally, the agreements governing our debt require that we maintain certain financial ratios, and contain affirmative and negative covenants that restrict our activities by, among other limitations, limiting our ability to incur additional indebtedness, merge or consolidate with other entities, make investments, create liens, sell assets and enter into transactions with affiliates. The covenants in our revolving credit facility (the Facility) include a Consolidated Leverage Ratio (total debt-to-Consolidated EBITDA) and a Consolidated Interest Coverage Ratio (Consolidated EBITDA to Consolidated Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a maximum Consolidated Leverage Ratio of 3.5:1.0. The company has also agreed that so long as any lender has any commitment under the Facility or any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.0:1.0 as of the last day of any fiscal quarter.

Our ability to comply with these financial restrictions and covenants is dependent on our future performance, which is subject to prevailing economic conditions and other factors, including factors that are beyond our control such as foreign exchange rates and interest rates. Our failure to comply with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt under that instrument and require us to prepay that debt before its scheduled due date. Also, an acceleration of the debt under certain of our debt instruments would trigger an event of default under other of our debt instruments.


Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

There was no share repurchase activity for the company's second quarter of 2019. On September 7, 2018, the Board of Directors authorized the repurchase of up to $2.00 billion of the company’s common stock. At June 29, 2019, $1.25 billion was available for future repurchases of the company’s common stock under this authorization.


Item 6.	Exhibits

See Exhibit Index on page 48.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



Date:	August 2, 2019	THERMO FISHER SCIENTIFIC INC.



		/s/ Stephen Williamson
		Stephen Williamson
		Senior Vice President and Chief Financial Officer



		/s/ Peter E. Hornstra
		Peter E. Hornstra
		Vice President and Chief Accounting Officer

THERMO FISHER SCIENTIFIC INC.

EXHIBIT INDEX



Exhibit Number		Description of Exhibit
10.1		Thermo Fisher Scientific Inc. Executive Severance Policy.*
10.2		Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers.*
31.1		Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2		Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS		XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH		XBRL Taxonomy Extension Schema Document.
101.CAL		XBRL Taxonomy Calculation Linkbase Document.
101.DEF		XBRL Taxonomy Definition Linkbase Document.
101.LAB		XBRL Taxonomy Label Linkbase Document.
101.PRE		XBRL Taxonomy Presentation Linkbase Document.
		The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to long-term debt of the Registrant or its consolidated subsidiaries.

_______________________

* Indicates management contract or compensatory plan, contract or arrangement.

** Certification is not deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.

Exhibit 10.1

THERMO FISHER SCIENTIFIC INC.

EXECUTIVE SEVERANCE POLICY

1. Introduction. The Thermo Fisher Scientific Inc. Executive Severance Policy (the “Policy”) is designed to provide separation pay and benefits to certain eligible Executives of Thermo Fisher Scientific Inc. (the “Company”) whose employment is involuntarily terminated without cause. This document constitutes the written instrument under which the Policy is maintained and supersedes any prior plan or practice of the Company that provides severance benefits to Executives, including without limitation, the relevant terms of any individual offer or employment letter or contract. Notwithstanding the foregoing sentence, if an Executive is party to an agreement with the Company providing for the payment of benefits in the event the employment of such Executive is terminated after a Change in Control (a “Change in Control Agreement”), such Change in Control Agreement shall not be terminated or cancelled by this Policy and such Change in Control Agreement shall survive and remain in effect in accordance with its own terms. In the event such Executive actually receives benefits under a Change in Control Agreement, such Executive shall not also be entitled to receive benefits under this Policy. This Policy shall become effective as of May 22, 2019.

2. Key Definitions.

As used herein, the following terms shall have the following respective meanings:

2.1 “Change in Control” means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d‑3 promulgated under the Exchange Act) 50% or more of either (i) the then‑outstanding shares of common stock of the Company (the “Outstanding Company Common Stock”) or (ii) the combined voting power of the then‑outstanding securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by the Company, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (iii) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this Section 1.1; or

(b) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the Board of Directors of a successor corporation

to the Company), where the term “Continuing Director” means at any date a member of the Board (i) who was a member of the Board on the effective date of the Policy or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or

(c) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a “Business Combination”), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then‑outstanding shares of common stock and the combined voting power of the then‑outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company's assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the “Acquiring Corporation”) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively; and (ii) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 50% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then‑outstanding securities of such corporation entitled to vote generally in the election of directors; or

(d) approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

2.2 “Cause” means the Executive's willful engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company. For purposes of this Section 2.2, no act or failure to act by the Executive shall be considered “willful” unless it is done, or omitted to be done, in bad faith and without reasonable belief that the Executive's action or omission was in the best interests of the Company.

2.3 “Continuation Period” means a period beginning on the date of termination of the Executive and continuing for 18 consecutive months in the case of an Officer and for 12 consecutive months in the case of an Executive who is not an Officer.

2.4 “Covered Employee” means an Executive who has been designated by the Company’s Board of Directors as an executive officer of the Company.

2.5 “Disability” means the Executive's inability, due to a physical or mental disability, for a period of 90 days, whether or not consecutive, during any 360-day period to perform the Executive’s duties on behalf of the Company, with or without reasonable accommodation as that term is defined under state or federal law. A determination of disability shall be made by a physician satisfactory to both the Executive and the Company, provided that if the Executive and the Company do not agree on a physician, the Executive and the Company shall each select a physician and these two together shall select a third physician, whose determination as to disability shall be binding on all parties.

2.6 “Executive” means an employee of the Company who has been classified by the Company as a Career Band 13 Employee or an officer; provided, however, that an employee who is party to an agreement with the Company providing for the payment of separation benefits in the event the employment of such Executive is terminated without cause (other than a Change in Control Agreement) shall not be considered to be an Executive for purposes of this Policy.

2.7 “Officer” means an Executive who has been designated by the Company’s Board of Directors as an officer of the Company.

2.8 “Severance Multiplier” means 1.5 for an Officer and 1.0 for an Executive who is not an Officer.

3. Not an Employment Contract. This Policy does not constitute a contract of employment or impose on the Company any obligation to retain any Executive as an employee and does not prevent any Executive from terminating employment at any time.

4. Benefits to Executives.

4.1 Compensation.

(a) Termination Without Cause. If an Executive's employment with the Company is terminated by the Company (other than for Cause, Disability or death) then the Executive shall be entitled to the following benefits:

(i) the Company shall pay to the Executive the aggregate of the following amounts:

(A) the Executive’s base salary through the date of termination, to the extent not previously paid, to be paid in a lump sum within 30 days after the date of termination;

(B) in the case of a Covered Employee, his or her Pro Rata Bonus. A Covered Employee’s Pro Rata Bonus shall be the product of (x) the target bonus amount that would have been payable to such Covered Employee for the year (or other award period) in which the date of termination occurs had the Covered Employee remained employed through the completion of the year (or other award period) and (y) a fraction, the numerator of which is the number of days in the current fiscal year (or award period) through the date of termination, and the

denominator of which is 365 (or total duration of the applicable award period), to be paid no later than the date bonus amounts are paid to similarly situated Executives, provided that a Pro Rata Bonus shall be payable only to the extent the applicable Company performance goals with respect to such bonus are achieved; and

(C) the Executive’s Severance Multiplier times (x) the Executive’s annual base salary as in effect immediately prior to the date of termination and (y) the Executive’s target bonus for the year in which termination occurs, in each case to be paid in a lump sum within 30 days after the date of termination; and

(ii) for the Executive’s Continuation Period, or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, the Company shall continue to provide medical, dental and life insurance benefits to the Executive and the Executive's family at least equal to those which would have been provided to them if the Executive's employment had not been terminated, in accordance with the applicable benefit plans in effect on the date of termination or, if more favorable to the Executive and the Executive’s family, in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies; provided, however, that (A) if the terms of a benefit plan do not permit continued participation therein by a former employee, then an equitable arrangement shall be made by the Company (such as a substitute or alternative plan) to provide as substantially equivalent a benefit as is reasonably possible and (B) if the Executive becomes reemployed with another employer and is eligible to receive a particular type of benefit (e.g., medical insurance benefits) from such employer on terms at least as favorable to the Executive and the Executive’s family as those being provided by the Company, then the Company shall no longer be required to provide those particular benefits to the Executive and the Executive’s family; and

(iii) to the extent not previously paid or provided, the Company shall timely pay or provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive following the Executive's termination of employment under any plan, program, policy, practice, contract or agreement of the Company and its affiliated companies (other than severance benefits) (such other amounts and benefits described in this clause (iii) shall be hereinafter referred to as the “Other Benefits”).

(b) Termination for Cause, Disability or Death. If the Company terminates the Executive's employment with the Company because of the Executive’s disability, the Executive’s death or for Cause, then the Company shall (i) pay the Executive or the Executive’s estate, in a lump sum in cash within 30 days after the date of termination, the Executive’s base salary through the date of termination and (ii) timely pay or provide to the Executive the Other Benefits.

4.2 Outplacement Services. In the event the Executive is terminated by the Company (other than for Cause, Disability or death), the Company shall provide outplacement services through one or more outside firms of the Executive’s choosing up to an aggregate of $20,000, with such services to extend until the earlier of (i) 12 months following the termination of the Executive’s employment or (ii) the date the Executive secures full time employment.

4.3 Mitigation. The Executive shall not be required to mitigate the amount of any payment or benefits provided for in this Section 4 by seeking other employment or otherwise. Further, except as provided in Section 4.1(a)(ii), the amount of any payment or benefits provided for in this Section 4 shall not be reduced by any compensation earned by the Executive as a result of employment by another employer, by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company or otherwise.

4.4 Release of Claims by Executive. The Executive shall not be entitled to any payments or other benefits hereunder unless the Executive executes and, if applicable, does not revoke, a full and complete release of claims and separation agreement, in the form to be provided by the Company.

4.5 Non-Compete Obligations. An Executive shall not be entitled to any payments or other benefits hereunder unless the Executive has executed a Noncompetition Agreement with the Company. Notwithstanding the foregoing, severance pay and benefits hereunder may, in the Company’s sole discretion, be contingent on an Executive’s written agreement to new, additional and/or superseding restrictive covenants (including but not limited to new, additional and/or superseding non-competition restrictions), whether as part of the Executive’s Release or in one or more separate documents.

5. Disputes. All claims by the Executive for benefits under this Agreement shall be directed to and determined by the Board and shall be in writing. Any denial by the Board of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial. The Board shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim. Any further dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the arbitrator's award in any court having jurisdiction.

6. Successors.

6.1 Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Policy to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company” shall mean the Company as defined above and any successor to its business or assets as aforesaid which assumes and agrees to perform this Agreement, by operation of law or otherwise.

6.2 Successor to Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive's personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Executive should die while any amount would still be payable to the Executive or the Executive’s family hereunder if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives or administrators of the Executive's estate.

7. Notice. All notices, instructions and other communications given hereunder or in connection herewith shall be in writing. Any such notice, instruction or communication shall be sent either (i) by registered or certified mail, return receipt requested, postage prepaid, or (ii) prepaid via a reputable nationwide overnight courier service, in each case addressed to the Company, at 168 Third Avenue, Waltham, Massachusetts and to the Executive at the Executive’s principal residence as currently reflected on the Company’s records (or to such other address as either the Company or the Executive may have furnished to the other in writing in accordance herewith). Any such notice, instruction or communication shall be deemed to have been delivered five business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent via a reputable nationwide overnight courier service. Either party may give any notice, instruction or other communication hereunder using any other means, but no such notice, instruction or other communication shall be deemed to have been duly delivered unless and until it actually is received by the party for whom it is intended.

8. Miscellaneous.

8.1 Severability. The invalidity or unenforceability of any provision of this Policy shall not affect the validity or enforceability of any other provision of this Policy, which shall remain in full force and effect.

8.2 Governing Law. The validity, interpretation, construction and performance of this Policy shall be governed by the internal laws of the Commonwealth of Massachusetts, without regard to conflicts of law principles.

8.3 Waivers. No waiver by the Executive at any time of any breach of, or compliance with, any provision of this Policy to be performed by the Company shall be deemed a waiver of that or any other provision at any subsequent time.

8.4 Tax Withholding. Any payments provided for hereunder shall be paid net of any applicable tax withholding required under federal, state or local law.

8.5 Amendments. This Policy may be amended or terminated by the Company at any time; provided that this Section 8.5 shall have no force or effect after the occurrence of a Change of Control.

9. Section 409A Compliance.

The following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided to the Executive under this Policy:

9.1 It is intended that each installment of the payments and benefits provided under Section 4 shall be treated as a separate “payment” for purposes of Section 409A of the Internal Revenue Code of 1986 and the guidance issued thereunder (“Section 409A”). Neither the Company nor the Executive shall have the right to accelerate or defer the delivery of any

such payments or benefits except to the extent specifically permitted or required by Section 409A.

9.2 If, as of the date of the “separation from service” of the Executive from the Company (determined as set forth below), the Executive is not a “specified employee” (within the meaning of Section 409A), then each installment of the payments and benefits shall be made on the dates and terms set forth in Section 4.

9.3 If, as of the date of the “separation from service” of the Executive from the Company, the Executive is a “specified employee” (within the meaning of Section 409A), then:

(a) Each installment of the payments and benefits due under Section 4, that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the Short-Term Deferral Period (as hereinafter defined) shall be treated as a short-term deferral within the meaning of Treasury Regulation § 1.409A-1(b)(4) to the maximum extent permissible under Section 409A. For purposes of this Policy, the “Short-Term Deferral Period” means the period ending on the later of the 15^th day of the third month following the end of the Executive’s tax year in which the separation from service occurs and the 15^th day of the third month following the end of the Company’s tax year in which the separation from service occurs; and

(b) Each installment of the payments and benefits due under Section 4 that is not described in clause (a), above, and that would, absent this subsection, be paid within the six-month period following the “separation from service” of the Executive from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, the Executive’s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following the Executive’s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of payments and benefits if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation § 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation § 1.409A-1(b)(9)(iii) must be paid no later than the last day of the Executive’s second taxable year following his taxable year in which the separation from service occurs.

9.4 The determination of whether and when a separation from service of the Executive from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation § 1.409A-1(h). Solely for purposes of this Section 9.4, “Company” shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code.

9.5 All reimbursements and in-kind benefits provided under the Policy shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A.

9.6 The provisions of Sections 4.4 and 4.5 shall be applied as follows: Payment of benefits under this Policy shall be made on (or, with respect to in kind benefits subject to Section 409A, commence on) the 30^th day following the Employee’s separation from service, provided that the Employee has by that time executed and submitted (and not revoked) the release of claims and separation agreement described in Section 4.4 and any documentation required pursuant to Section 4.5. Notwithstanding any other provision herein, in the case of a group termination program, the foregoing sentence shall be applied by substituting the words “60^th day” for the words “30^th day”.

9.7 The terms of this Policy shall be interpreted as necessary to provide payments that comply with (or are exempt from) the requirements of Section 409A.

Exhibit 10.2

NONCOMPETITION AGREEMENT

THIS AGREEMENT, dated as of _________ __, 2019, is made by and between __________________ (the "Employee"), and Thermo Fisher Scientific Inc., a Delaware corporation whose principal offices are located at 168 Third Avenue, Waltham, Massachusetts 02451 ("Employer").

WHEREAS, Employer has developed and continues to develop and use certain trade secrets, customer lists and other proprietary and confidential information and data, which Employer has spent a substantial amount of time, effort and money, and will continue to do so in the future, to develop or acquire and to promote and increase the related good-will.

NOW, THEREFORE, in consideration of Employee’s new employment or continued employment by Employer or a subsidiary or affiliate thereof, and Employee’s compensation, in particular additional valuable consideration including, but not limited to Employee’s eligibility to participate in Employer’s Executive Severance Policy, Employee’s eligibility to receive equity compensation awards, and Employee’s access to Confidential Information and Trade Secrets belonging to Employer (as defined in the Company Information and Invention Agreement, the Information and Technology Agreement, or any predecessor agreement Employee may have signed, collectively referred to hereinafter as “Company Information and Invention Agreement”), and for other good and sufficient consideration, which is conditioned, at least in part, upon Employee’s execution and delivery of this Agreement, Employee understands and agrees to the following:

Section 1. Employee recognizes and acknowledges that it is essential for the proper protection of the Employer’s legitimate business interests that Employee be restrained for a reasonable period following the termination of Employee’s employment with the Employer, either voluntarily or involuntarily, from competing with Employer as set forth below.

Employee acknowledges and agrees that during the term of Employee’s employment with Employer, and for a period of twelve (12) months thereafter, Employee will not, directly or indirectly, engage, participate or invest in or be employed by any business within the Restricted Area, as defined below, which: (i) develops or manufactures products which are competitive with or similar to products developed or manufactured by Employer; (ii) distributes, markets or otherwise sells, either through a direct sales force or through the use of the Internet, products manufactured by others which are competitive with or similar to products distributed, marketed or sold by Employer; or (iii) provide services, including the use of the Internet to sell, market or distribute products, which are competitive with or similar to services provided by Employer, including, in each case, any products or services Employer has under development or which are the subject of active planning at any time during the term of Employee’s employment. The foregoing restrictions shall apply regardless of the capacity in which Employee engages, participates or invests in or is employed by a given business, whether as owner, partner, shareholder, consultant, agent, employee, co-venturer or otherwise. Employee further agrees that in the event Employee breaches his or her fiduciary duty to Employer or unlawfully takes Employer property, the restrictions in this Section 1 shall be extended to twenty-four (24) months.

“Restricted Area” shall mean each state and territory of the United States of America and each country of the world outside of the United States of America in which Employer had developed, marketed, sold and/or distributed its products and/or services within the last two (2) years of Employee’s employment.

Section 2. During the term of Employee’s employment with Employer and for a period of eighteen (18) months after termination of the Employee’s employment with the Employer for any reason, Employee will not: (i) employ, hire, solicit, induce or identify for employment or attempt to employ, hire, solicit, induce or identify for employment, directly or indirectly, any employee(s) of the Employer to leave his or her employment and become an employee, consultant or representative of any other entity including, but not limited to, Employee’s new employer, if any; and/or (ii) solicit, aid in or encourage the solicitation of, contract with, aid in or encourage the contracting with, service, or contact any person or entity which is or was, within the two (2) years prior to Employee’s termination of employment with Employer, a customer or client of Employer, for purposes of marketing, offering or selling a product or service competitive with Employer.

Section 3. For the period of eighteen (18) months immediately following the end of Employee’s employment by Employer, Employee will inform each new employer, prior to accepting employment, of the existence of this Agreement and provide that employer with a copy of this Agreement.

Section 4. Employee understands and agrees that the provisions of this Agreement shall not prevent Employee from acquiring or holding publicly traded stock or other publicly traded securities of a business, so long as Employee’s ownership does not exceed 1% percent of the outstanding securities of such company of the same class as those held by Employee.

Section 5. Employee acknowledges that the time, geographic area and scope of activity limitations set forth herein are reasonable and necessary to protect the Employer’s legitimate business interests. However, if in any judicial proceeding a court refuses to enforce this Agreement, whether because the time limitation is too long or because the restrictions contained herein are more extensive (whether as to geographic area, scope of activity or otherwise) than is necessary to protect the legitimate business interests of Employer, it is expressly understood and agreed between the parties hereto that this Agreement is deemed modified to the extent necessary to permit this Agreement to be enforced in any such proceedings.

Section 6. Employee further acknowledges and agrees that it would be difficult to measure any damages caused to Employer which might result from any breach by Employee of any of the promises set forth in this Agreement, and that, in any event, money damages would be an inadequate remedy for any such breach. Accordingly, Employee acknowledges and agrees that if he or she breaches or threatens to breach, any portion of this Agreement, Employer shall be entitled, in addition to all other remedies that it may have: (i) to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to Employer; and (ii) to be relieved of any obligation to provide any further payment or

benefits to Employee or Employee’s dependents.

Section 7. Employee acknowledges and agrees that should it become necessary for Employer to file suit to enforce the covenants contained herein, and any court of competent jurisdiction awards the Employer any damages and/or an injunction due to the acts of Employee, then the Employer shall be entitled to recover its reasonable costs incurred in conducting the suit including, but not limited, reasonable attorneys’ fees and expenses.

Section 8. The Employee acknowledges and agrees that this Agreement does not constitute a contract of employment and does not imply that Employer or any of its subsidiaries will continue the Employee's employment for any period of time.

Section 9. This Agreement represents the entire understanding of the parties with respect to the subject matter hereof and any previous agreements or understandings between the parties regarding the subject matter hereof are merged into and superseded by this Agreement.

Section 10. This Agreement cannot be modified, amended or changed, nor may compliance with any provision hereof be waived, except by an instrument in writing executed by the party against whom enforcement of such modification, amendment, change or waiver is sought. Any waiver by a party of the breach of any provision of this Agreement shall not operate or be construed as a waiver of any other breach of such provision or of any breach of any other provision of this Agreement. The failure of a party to insist upon strict compliance with any provision of this Agreement at any time shall not deprive such party of the right to insist upon strict compliance with such provision at any other time or of the right to insist upon strict compliance with any other provision hereof at any time.

Section 11. All notices, requests, demands, consents and other communications which are required or permitted hereunder shall be in writing, and shall be deemed given when actually received or if earlier, two days after deposit with the U.S. postal authorities, certified or registered mail, return receipt requested, postage prepaid or two days after deposit with an internationally recognized air courier or express mail, charges prepaid, addressed as follows:

If to Employer:

Thermo Fisher Scientific Inc.

168 Third Avenue

Waltham, Massachusetts 02451

Attention: General Counsel

If to the Employee, at the address set forth above, or to such other address as any party hereto may designate in writing to the other party, specifying a change of address for the purpose of this Agreement.

Section 12. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Section 13. This Agreement shall be construed and interpreted in accordance with, and shall be governed exclusively by, the laws of the Commonwealth of Massachusetts and the federal laws of the United States of America. Any action concerning this Agreement shall be commenced and maintained exclusively in the state or federal courts in Suffolk County, Massachusetts unless Employer, in its sole discretion, chooses to pursue the action in the federal or state courts in the state or county in which Employee resides. Employee hereby irrevocably submits to the personal jurisdiction and venue of all courts located in Suffolk County, Massachusetts, and agrees that he or she will not challenge personal jurisdiction or venue of such courts or seek to have any action concerning this Agreement dismissed or transferred based on personal jurisdiction, venue, inconvenience, or otherwise.

Section 14. Employee agrees that, in the event of any change in his or her position, title, compensation, duties, location, or any other aspect of his or her employment, including any interruption in his or her employment, such change or interruption shall not cause this Agreement to terminate, nor shall it affect in any way Employee’s obligations under this Agreement.

Section 15. EMPLOYEE ACKNOWLEDGES THAT HE OR SHE HAS CAREFULLY READ THIS AGREEMENT AND HAS BEEN GIVEN AT LEAST TEN (10) BUSINESS DAYS TO REVIEW AND SIGN THIS AGREEMENT, DURING WHICH TIME EMPLOYEE HAS HAD THE RIGHT TO CONSULT WITH AN ATTORNEY OF EMPLOYEE'S OWN CHOOSING AT EMPLOYEE’S OWN EXPENSE. EMPLOYEE FURTHER ACKNOWLEDGES THAT HE OR SHE FULLY UNDERSTANDS THE CONTENT AND EFFECT OF THIS AGREEMENT AND AGREES TO ALL OF THE PROVISIONS CONTAINED HEREIN. EMPLOYEE AGREES THAT VOLUNTARILY SIGNING THIS AGREEMENT BEFORE THE EXPIRATION OF THE 10 BUSINESS DAYS SHALL SERVE AS A WAIVER OF THE 10 DAY REVIEW PERIOD.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.



EMPLOYEE:	THERMO FISHER SCIENTIFIC INC.
	By:
[Insert Name]		Name: Lisa Britt
		Title: Senior Vice President,
		Chief Human Resources Officer

Exhibit 31.1

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Marc N. Casper, certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 2, 2019



	/s/ Marc N. Casper
	Marc N. Casper President and Chief Executive Officer

Exhibit 31.2

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen Williamson, certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 2, 2019



	/s/ Stephen Williamson
	Stephen Williamson Senior Vice President and Chief Financial Officer

Exhibit 32.1

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended June 29, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, President and Chief Executive Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 2, 2019



	/s/ Marc N. Casper
	Marc N. Casper President and Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

THERMO FISHER SCIENTIFIC INC.

CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended June 29, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Stephen Williamson, Senior Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 2, 2019



	/s/ Stephen Williamson
	Stephen Williamson Senior Vice President and Chief Financial Officer